Immuron Limited (IMRN) 20-F 29 Oct 21 2021 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Jun. 30, 2021shares
Document Information Line Items
Entity Registrant Name	IMMURON LIMITED
Trading Symbol	IMRN
Document Type	20-F
Current Fiscal Year End Date	--06-30
Entity Common Stock, Shares Outstanding	227,246,596
Amendment Flag	false
Entity Central Index Key	0001660046
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	000-38104
Entity Incorporation, State or Country Code	C3
Entity Address, Address Line One	Level 3, 62 Lygon Street
Entity Address, City or Town	Carlton South
Entity Address, Postal Zip Code	3053
Entity Address, Country	AU
Title of 12(b) Security	American Depositary Shares, each representing 40 Ordinary Shares
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Accounting Standard	International Financial Reporting Standards
Business Contact
Document Information Line Items
Entity Address, Address Line One	Level 3, 62 Lygon Street
Entity Address, City or Town	Carlton South
Entity Address, Postal Zip Code	3053
Entity Address, Country	AU
Contact Personnel Name	Dr. Jerry Kanellos
City Area Code	61
Local Phone Number	3 9822 7735

Consolidated Statement of Profi

Consolidated Statement of Profit or Loss and Other Comprehensive Income - AUD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Profit or loss [abstract]
Revenue from contracts with customers	$ 145,776	$ 2,518,566	$ 2,387,426
Cost of Goods Sold	(51,071)	(688,836)	(667,371)
Gross Profit	94,705	1,829,730	1,720,055
Other Income	617,110	473,674	532,050
Other gains/(losses) – net	(1,342,293)	11,335	38,413
General and administrative expenses	(3,978,679)	(3,703,990)	(3,694,306)
Share-based payment expenses	(2,116,013)	533,912	(1,343,500)
Research and development expenses	(1,367,054)	(1,178,685)	(1,044,528)
Selling and marketing expenses	(287,684)	(871,551)	(864,644)
Operating loss	(8,379,908)	(2,905,575)	(4,656,460)
Finance income	9,204		39
Finance expenses	(13,761)	(21,631)
Finance costs - net	(4,557)	(21,631)	39
Loss Before Income Tax	(8,384,465)	(2,927,206)	(4,656,421)
Income Tax Expense
Loss for the Period	(8,384,465)	(2,927,206)	(4,656,421)
Other comprehensive income
Exchange differences on translation of foreign operations	(14,953)	102,938	61,846
Total Comprehensive Loss for the Period	$ (8,399,418)	$ (2,824,268)	$ (4,594,575)
Basic/Diluted Loss per Share (in cents per share) (in Dollars per share)	$ (3.79)	$ (1.66)	$ (3.22)

Consolidated Statement of Finan

Consolidated Statement of Financial Position - AUD ($)	Jun. 30, 2021	Jun. 30, 2020
Current Assets
Cash and cash equivalents	$ 25,047,281	$ 3,250,468
Trade and other receivables	334,707	327,689
Inventories	292,532	797,690
Other current assets	78,258	33,194
Total Current Assets	25,752,778	4,409,041
Non-Current Assets
Plant and equipment	33,741	70,773
Inventories	1,266,587	1,722,349
Total Non-Current Assets	1,300,328	1,793,122
TOTAL ASSETS	27,053,106	6,202,163
Current Liabilities
Trade and other payables	758,494	384,397
Provision for sales returns	213,024
Employee benefit obligations	129,837	89,838
Other current liabilities	20,498	42,176
Total Current Liabilities	1,121,853	516,411
Non-Current Liabilities
Employee benefit obligations	36,196	22,910
Other non-current liabilities		18,929
Total Non-Current Liabilities	36,196	41,839
TOTAL LIABILITIES	1,158,049	558,250
NET ASSETS	25,895,057	5,643,913
EQUITY
Issued capital	88,361,303	62,426,991
Reserves	3,466,642	1,133,345
Accumulated losses	(65,932,888)	(57,916,423)
TOTAL EQUITY	$ 25,895,057	$ 5,643,913

Consolidated Statement of Chang

Consolidated Statement of Changes in Equity - AUD ($)	Issued Capital	Reserves	Accumulated Losses	Total
Balance at Jun. 30, 2018	$ 58,237,314	$ 3,096,308	$ (52,894,272)	$ 8,439,350
Loss after income tax expense for the year			(4,656,421)	(4,656,421)
Other comprehensive income for the period		61,846		61,846
Total comprehensive loss for the period		61,846	(4,656,421)	(4,594,575)
Transactions with owners in their capacity as owners
Shares issued, net of costs	2,052,461			2,052,461
Options/warrants issued/expensed		1,453,900		1,453,900
Options/warrants exercised	100	(100)
Options/warrants forfeited		(311,635)	311,635
Balance at Jun. 30, 2019	60,289,875	4,300,319	(57,239,058)	7,351,136
Transactions with owners in their capacity as owners
Change in accounting policy			(1,479)	(1,479)
Revised total equity at 1 July 2019	60,289,875	4,300,319	(57,239,058)	7,351,136
Loss after income tax expense for the year			(2,927,206)	(2,927,206)
Other comprehensive income for the period		102,938		102,938
Total comprehensive loss for the period		102,938	(2,927,206)	(2,824,268)
Shares issued, net of costs	1,652,436			1,652,436
Options/warrants issued/expensed	484,680	(484,680)
Options/warrants forfeited		(2,251,320)	2,251,320
Re-valuation of options issued in prior period		(607,000)		(607,000)
Share-based payment expenses		73,088		73,088
Balance at Jun. 30, 2020	62,426,991	1,133,345	(57,916,423)	5,643,913
Loss after income tax expense for the year			(8,384,465)	(8,384,465)
Other comprehensive income for the period		(14,953)		(14,953)
Total comprehensive loss for the period		(14,953)	(8,384,465)	(8,399,418)
Transactions with owners in their capacity as owners
Shares issued, net of costs	24,386,005			24,386,005
Options/warrants issued/expensed		3,003,060		3,003,060
Options/warrants exercised	1,329,307	(213,722)		1,115,585
Options/warrants forfeited		(368,000)	368,000
Shares issued to directors	145,912			145,912
Transfer to share capital	73,088	(73,088)
Balance at Jun. 30, 2021	$ 88,361,303	$ 3,466,642	$ (65,932,888)	$ 25,895,057

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - AUD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Cash flows Related to Operating Activities
Receipts from customers	$ 192,185	$ 2,914,614	$ 2,619,477
Payments to suppliers and employees	(4,865,633)	(6,748,674)	(5,608,262)
Other - R&D tax concession refund	358,280	531,828	1,190,206
Government grants and other grants received	236,421	154,904
Net Cash Flows Used In Operating Activities	(4,078,747)	(3,147,328)	(1,798,579)
Cash Flows Related to Investing Activities
Payment for purchases of plant and equipment	(6,630)	(864)	(2,047)
Interest received	9,204		39
Net Cash Flows (Used In)/From Investing Activities	2,574	(864)	(2,008)
Cash Flows Related to Financing Activities
Proceeds from issues of securities	29,281,421	1,957,164	2,894,238
Capital raising costs	(2,746,871)	(374,728)	(825,055)
Proceeds from borrowings	212,794
Repayment of borrowings	(212,794)	(366,655)
Principal elements of lease payments	(40,607)	(41,390)
Interest and other costs of finance paid	(13,761)	(17,439)
Net Cash Flows From Financing Activities	26,480,182	1,156,952	2,069,183
Net increase in cash and cash equivalents	22,404,009	(1,991,240)	268,596
Cash and cash equivalents at the beginning of the year	3,250,468	5,119,887	4,727,430
Effects of exchange rate changes on cash and cash equivalents	(607,196)	121,821	123,861
Cash and Cash Equivalents at the End of the Year	$ 25,047,281	$ 3,250,468	$ 5,119,887

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2021
Disclosure of significant accounting policies [text block] [Abstract]
Summary of Significant Accounting Policies	Note 1. Summary of Significant Accounting Policies Corporate Information The consolidated financial report of Immuron Limited (“the Company”) for the year ended June 30, 2021, 2020 and 2019 was authorized for issue in accordance with a resolution of the Directors on October 29, 2021. Immuron Limited is a listed public company limited by shares incorporated and domiciled in Australia whose shares are publicly traded on the Australian Securities Exchange (ASX) and The NASDAQ Capital Market (“NASDAQ”). The Group’s principal activity is oral immunotherapy research and development and product sales focused on bovine-colostrum enriched with antibodies of choice for the treatment and prevention of a range of infectious diseases. Product sales comprise Travelan which is indicated to reduce the risk of contracting travelers’ diarrhea and Protectyn an OTC immune supplement for GI tract and liver health. (a) Basis of preparation These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board and the Corporations Act 2001 (i) Compliance with IFRS The consolidated financial statements of the Immuron Limited group also comply with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). (ii) Historical cost convention The financial statements have been prepared on a historical cost basis. (iii) Significant estimates and judgements Going concern The group is in a position to meet future commitments in the current business cycle and pay its debts as and when they fall due. Furthermore, the group is able to progress its research and development programs for at least the next 12 months. The annual report has been prepared on a going concern basis. Accordingly, the annual report does not include adjustments relating to the recoverability and classification of recorded asset amounts, or the amounts and classification of liabilities that might be necessary should the group not continue as a going concern. COVID-19 Judgement has been exercised in considering the impacts that the Coronavirus (COVID-19) pandemic has had, or may have, on the group based on known information. This consideration extends to the nature of the products and services offered, customers, supply chain, staffing and geographic regions in which the group operates. Sales of Travelan have significantly dropped from March 2020 and as at reporting date it is unknown the prolonged effect that COVID-19 will continue to have on sales. This note provides a list of the significant accounting policies adopted in the preparation of these consolidated financial statements to the extent they have not already been disclosed in the other notes above. These policies have been consistently applied to all the years presented, unless otherwise stated. The financial statements are for the group consisting of Immuron Limited and its subsidiaries. (iv) New standards and interpretations not yet adopted There are no standards that are not yet effective and that would be expected to have a material impact on the Company in the current or future reporting years and on foreseeable future transactions. (v) Revision of immaterial error During the year ended June 2020 the following immaterial error corrections were identified. Representative warrants Immuron Limited raised capital in June 2017 and May 2019, representative warrants were included as part of these public offerings. These were not identified and accounted for at the time of these capital raisings. Management has undertaken an assessment of the impact of this and concluded this to be an immaterial error. This has been corrected in the prior year by restating prior period financial statements presented and the related notes included herein to include the representative warrants. Reserves as of 30 June 2017 has been revised to increase by A$489,586 for the June 2017 representative warrants (1,220,000 options) with a corresponding decrease in share capital of the same amount. The impact of the 2017 revision has been also reflected in the 30 June 2018 and 30 June 2019 years presented. Reserves as of 30 June 2019 has been revised to increase by A$110,400 for the May 2019 representative warrants (800,000 options) with a corresponding decrease in share capital of the same amount. Summary of significant accounting policies The following is a summary of the material accounting policies adopted by the Company in the preparation of the financial report. The accounting policies have been consistently applied, unless otherwise stated. (b) Principles of consolidation (i) Subsidiaries Subsidiaries are all entities (including structured entities) over which the group has control. The group controls an entity when the group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the group. They are deconsolidated from the date that control ceases. The acquisition method of accounting is used to account for business combinations by the group. Intercompany transactions, balances and unrealized gains on transactions between group companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the group. (c) Segment reporting Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. This has been identified as the executive management team consisting of the CEO and COO. (d) Foreign currency translation (i) Functional and presentation currency Items included in the financial statements of each of the group’s entities are measured using the currency of the primary economic environment in which the entity operates (‘the functional currency’). The consolidated financial statements are presented in Australian dollar (“A$” or “$”), which is Immuron Limited’s functional and presentation currency. (ii) Transactions and balances Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates are generally recognized in profit or loss. Foreign exchange gains and losses that relate to borrowings are presented in the consolidated statement of profit or loss and other comprehensive income, within finance costs. All other foreign exchange gains and losses are presented in the consolidated statement of profit or loss and other comprehensive income on a net basis within other gains/(losses). Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. For example, translation differences on non-monetary assets and liabilities such as equities held at fair value through profit or loss are recognized in profit or loss as part of the fair value gain or loss and translation differences on non-monetary assets such as equities classified as at fair value through other comprehensive income are recognized in other comprehensive income. (iii) Group companies The results and financial position of foreign operations (none of which has the currency of a hyperinflationary economy) that have a functional currency different from the presentation currency are translated into the presentation currency as follows: ● assets and liabilities for each consolidated balance sheet presented are translated at the closing rate at the date of that consolidated balance sheet; ● income and expenses for each consolidated statement of profit or loss and consolidated statement of profit or loss and other comprehensive income are translated at average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions); and ● all resulting exchange differences are recognized in other comprehensive income. On consolidation, exchange differences arising from the translation of any net investment in foreign entities, and of borrowings and other financial instruments designated as hedges of such investments, are recognized in other comprehensive income. When a foreign operation is sold or any borrowings forming part of the net investment are repaid, the associated exchange differences are reclassified to profit or loss, as part of the gain or loss on sale. (e) Revenue recognition (i) Sale of hyperimmune products Revenue arises mainly from the sale hyperimmune products. To determine whether to recognize revenue, the group follows the process of identifying the contract with a customer, identifying the performance obligations, determining the transaction price, allocating the transaction price to the performance obligations and recognising revenue when performance obligations are satisfied. Revenue from the sale of hyperimmune products is recognized when or as the group transfers control of the assets to the customer. There is no variable consideration or significant cost to obtain the contract. There are no warranties and no refunds. Returns are provided where this is outlined in a customer agreement. (ii) Financing components The group does not expect to have any contracts where the period between the transfer of the promised goods or services to the customer and payment by the customer exceeds one year. As a consequence, the group does not adjust any of the transaction prices for the time value of money. (f) Government grants Grants from the government are recognized at their fair value where there is a reasonable assurance that the grant will be received and the group will comply with all attached conditions. Fair value of other grants The group’s other grant income consists of grants received by the group with relation to COVID-19. Grants are recognized as other income when the group is reasonable assured that it will comply with the conditions attaching to it and the grant will be received. For the year ended 30 June 2020, the group has recognized A$154,904 in assistance packages. (g) Income tax The income tax expense or credit for the period is the tax payable on the current period’s taxable income based on the applicable income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses. The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the company and its subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities. Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, deferred tax liabilities are not recognized if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. Deferred tax assets are recognized only if it is probable that future taxable amounts will be available to utilize those temporary differences and losses. Current and deferred tax is recognized in profit or loss, except to the extent that it relates to items recognized in other comprehensive income or directly in equity. In this case, the tax is also recognized in other comprehensive income or directly in equity, respectively. (h) AASB Interpretation 23 Uncertainty over Income Tax Treatments Interpretation 23 requires the assessment of whether the effect of uncertainty over income tax treatments should be included in the determination of taxable profit (tax loss), tax bases, unused tax losses, unused tax credits and tax rates. The Interpretation outlines the requirements to determine whether an entity considers uncertain tax treatments separately, the assumptions an entity makes about the examination of tax treatments by taxation authorities, how an entity determines taxable profit (tax loss), tax bases, unused tax losses, unused tax credits and tax rates and how an entity considers changes in facts and circumstances. The group has adopted Interpretation 23 from 1 July 2019, based on an assessment of whether it is ‘probable’ that a taxation authority will accept an uncertain tax treatment. This assessment takes into account that for certain jurisdictions in which the group operates, a local tax authority may seek to open a group’s books as far back as inception of the group. Where it is probable, the group has determined tax balances consistently with the tax treatment used or planned to be used in its income tax filings. Where the group has determined that it is not probable that the taxation authority will accept an uncertain tax treatment, the most likely amount or the expected value has been used in determining taxable balances (depending on which method is expected to better predict the resolution of the uncertainty). There has been no impact from the adoption of Interpretation 23 in this reporting period. (i) Leases The accounting policies for the group's leases are explained in note 14(iii). (j) Impairment of assets An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period. (k) Cash and cash equivalents For the purpose of presentation in the consolidated statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities in the consolidated balance sheet. (l) Trade receivables Trade receivables are recognized initially at fair value and subsequently measured at amortised cost using the effective interest method, less loss allowance. See note 21(b) for a description of the group’s impairment policies. (i) Classification as trade receivables Trade receivables are amounts due from customers for goods sold or services performed in the ordinary course of business. They are generally due for settlement within 30 days and therefore are all classified as current. Trade receivables are recognized initially at the amount of consideration that is unconditional unless they contain significant financing components, when they are recognized at fair value. The group holds the trade receivables with the objective to collect the contractual cash flows and therefore measures them subsequently at amortised cost using the effective interest method. Details about the group’s impairment policies and the calculation of the loss allowance are provided below. (ii) Accrued receivables These amounts primarily comprise receivables from the Australian Taxation Office in relation to the R&D tax incentive. (iii) Fair value of trade and other receivables Due to the short-term nature of the current receivables, their carrying amount is considered to be the same as their fair value. (iv) Impairment and risk exposure Information about the impairment of trade receivables and the group’s exposure to credit risk and foreign currency risk can be found in note 21. (m) Inventories Raw materials and stores, work in progress and finished goods Raw materials and stores, work in progress and finished goods are stated at the lower of cost and net realisable value. Cost comprises direct materials, direct labour and an appropriate proportion of variable and fixed overhead expenditure, the latter being allocated on the basis of normal operating capacity. Costs are assigned to individual items of inventory on the basis of weighted average costs. Costs of purchased inventory are determined after deducting rebates and discounts. Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. (n) Investments and other financial assets (i) Classification The group classifies its financial assets in the following measurement categories: ● those to be measured subsequently at fair value (either through other comprehensive income or through profit or loss); and ● those to be measured at amortised cost. The classification depends on the group’s business model for managing the financial assets and the contractual terms of the cash flows. For assets measured at fair value, gains and losses will either be recorded in profit or loss and other comprehensive income. For investments in equity instruments that are not held for trading, this will depend on whether the group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through other comprehensive income (FVOCI). (ii) Recognition and derecognition Regular way purchases and sales of financial assets are recognized on trade-date, the date on which the group commits to purchase or sell the asset. Financial assets are derecognized when the rights to receive cash flows from the financial assets have expired or have been transferred and the group has transferred substantially all the risks and rewards of ownership. (iii) Measurement At initial recognition, the group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (FVPL), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVPL are expensed in profit or loss. (iv) Impairment The group assesses on a forward looking basis the expected credit losses associated with its debt instruments carried at amortised cost. The impairment methodology applied depends on whether there has been a significant increase in credit risk. For trade receivables, the group applies the simplified approach permitted by IFRS 9, which requires expected lifetime losses to be recognized from initial recognition of the receivables, see note 21(b) for further details. (v) Income recognition Interest income Interest income is recognized using the effective interest method. When a receivable is impaired, the group reduces the carrying amount to its recoverable amount, being the estimated future cash flow discounted at the original effective interest rate of the instrument, and continues unwinding the discount as interest income. Interest income on impaired loans is recognized using the original effective interest rate. (o) Property, plant and equipment Property, plant and equipment is stated at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items. Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred. Depreciation is calculated using the straight-line method to allocate their cost or revalued amounts, net of their residual values, over their estimated useful lives or, in the case of leasehold improvements and certain leased plant and equipment, the shorter lease term as follows: ● Plant and equipment 2 - 5 years ● Furniture, fittings and equipment 3 - 15 years ● Right-of-use assets 3 years The assets’ residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period. An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying amount is greater than its estimated recoverable amount. Gains and losses on disposals are determined by comparing proceeds with carrying amount. These are included in profit or loss. (p) Intangible assets Research and development Expenditure on research activities, undertaken with the prospect of obtaining new scientific or technical knowledge and understanding, is recognized in the consolidated statement of profit or loss and other comprehensive income as an expense when it is incurred. Expenditure on development activities, being the application of research findings or other knowledge to a plan or design for the production of new or substantially improved products or services before the start of commercial production or use, is capitalised if it is probable that the product or service is technically and commercially feasible, will generate probable economic benefits, adequate resources are available to complete development and cost can be measured reliably. Other development expenditure is recognized in the consolidated statement of profit or loss and other comprehensive income as an expense as incurred. (q) Trade and other payables These amounts represent liabilities for goods and services provided to the group prior to the end of financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting period. They are recognized initially at their fair value and subsequently measured at amortised cost using the effective interest method. (r) Employee benefits (i) Short-term obligations Liabilities for wages and salaries, including non-monetary benefits, annual leave and accumulating sick leave that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognized in respect of employees’ services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in the balance sheet. (ii) Other long-term employee benefit obligations In some countries, the group also has liabilities for long service leave and annual leave that are not expected to be settled wholly within 12 months after the end of the period in which the employees render the related service. These obligations are therefore measured as the present value of expected future payments to be made in respect of services provided by employees up to the end of the reporting period using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the end of the reporting period of high-quality corporate bonds with terms and currencies that match, as closely as possible, the estimated future cash outflows. Remeasurements as a result of experience adjustments and changes in actuarial assumptions are recognized in profit or loss. The obligations are presented as current liabilities in the balance sheet if the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period, regardless of when the actual settlement is expected to occur. (iii) Share-based payments Share-based compensation benefits are provided to employees via the ‘executive share and option plan’ (ESOP). Information relating to these schemes is set out in note 19. Employee options The fair value of options granted under the ESOP is recognized as a share-based payment expense with a corresponding increase in equity. The total amount to be expensed is determined by reference to the fair value of the options granted: - including any market performance conditions (e.g. the company’s share price); - excluding the impact of any service and non-market performance vesting conditions (e.g. profitability, sales growth targets and remaining an employee of the company over a specified time period); and - including the impact of any non-vesting conditions (e.g. the requirement for employees to save or holdings shares for a specific period of time). The total expense is recognized over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. At the end of each period, the entity revises its estimates of the number of options that are expected to vest based on the non-market vesting and service conditions. It recognizes the impact of the revision to original estimates, if any, in profit or loss, with a corresponding adjustment to equity. (s) Contributed equity Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds. (t) Loss per share (i) Basic loss per share Basic loss per share is calculated by dividing: ● the loss attributable to owners of the company, excluding any costs of servicing equity other than ordinary shares ● by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the year. (ii) Diluted loss per share Diluted loss per share adjusts the figures used in the determination of basic loss per share to take into account: ● the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares, and ● the weighted average number of additional ordinary shares that would have been outstanding assuming the conversion of all dilutive potential ordinary shares. (u) Rounding of amounts The company is of a kind referred to in ASIC Legislative Instrument 2016/191, relating to the ‘rounding off’ of amounts in the financial statements. Amounts in the financial statements have been rounded off in accordance with the instrument to the nearest dollar. (v) Goods and services tax (GST) Revenues, expenses and assets are recognized net of the amount of associated GST, unless the GST incurred is not recoverable from the taxation authority. In this case it is recognized as part of the cost of acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the taxation authority is included with other receivables or payables in the consolidated balance sheet. Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the taxation authority, are presented as operating cash flows. Critical Accounting Estimates and Judgments Management evaluates estimates and judgments incorporated into the financial statements based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both internally and externally. Share-based payments The value attributed to share options and remunerations shares issued is an estimate calculated using an appropriate mathematical formula based on an option pricing model. The choice of models and the resultant option value require assumptions to be made in relation to the likelihood and timing of the conversion of the options to shares and the value of volatility of the price of the underlying shares. Fair value of options granted The assessed fair value of options at grant date was determined using the Black-Scholes option pricing model that takes into account the exercise price, term of the option, security price at grant date and expected price volatility of the underlying security, the expected dividend yield, the risk-free interest rate for the term of the security and certain probability assumptions. Impairment of inventories The provision for impairment of inventories assessment requires a degree of estimation and judgement. The level of the provision is assessed by taking into account the recent sales experience, the ageing of inventory, and in particular, the shelf life of inventories that affects obsolescence. Expected shelf-life is reassessed on a regular basis with reference to stability tests which are conducted by an expert engaged by the Company. A comprehensive stability study was completed in September 2019 and the reported findings support a shelf life of at least 130 months for the colostrum drug substance. There was a $328,833 (2020: Nil Nil Inventory split During the year ended 30 June 2021, management performed an assessment of its raw materials and utilisation within 12 months from reporting date. Management determined no raw materials relating to Colostrum will be consumed within 12 months from reporting date (2020: Nil Provision for employee benefits Provision for employee benefits represents amounts accrued for annual leave and long service leave. The current portion for this provision includes the total amount accrued for annual leave entitlements and the amounts accrued for long service leave entitlements that have vested due to employees having completed the required period of service. Refer to note 1(q) for policies on provisions. R&D tax incentive The Group’s research and development activities are eligible under an Australian Government tax incentive for eligible expenditure from July 1, 2011. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. For the year ended June 30, 2021 the Group has recorded other income of A$306,154 (2020: A$308,225) to recognise income over the year necessary to match the R&D tax incentive on a systematic basis with the costs that they are intended to compensate. Furthermore, the group subsequently received additional A$50,055 in current financial year as part of the R&D claim for financial year ended 30 June 2020. Fair value measurement hierarchy The preparation of the financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgments, estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgments, estimates, and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgments and estimates will seldom equal the related actual results. The judgments, estimates and assumptions that have a significant risk of

Revenue and other income

Revenue and other income	12 Months Ended
	Jun. 30, 2021
Disclosure of revenue [text block] [Abstract]
Revenue and other income	Note 2. Revenue and other income 30 June 30 June 30 June A$ A$ A$ Revenue Revenue from Operating Activities Revenue from contracts with customers 145,776 2,518,566 2,387,426 Total Revenue from Operating Activities 145,776 2,518,566 2,387,426 Other Income Australian Federal R&D Tax Concession Refund 356,209 308,225 531,005 COVID-19 government assistance 161,600 154,904 - R&D grants 74,821 - - Other income 24,480 10,545 1,045 Total Other Income 617,110 473,674 532,050 Other Gains/(Losses) – Net Net foreign exchange gains/(losses) (582,528 ) 11,335 51,807 Net impairment losses (759,765 ) - (13,394 ) Total Other Gains/(Losses) – Net (1,342,293 ) 11,335 38,413 Notes (i) Sale of hyperimmune products Revenue arises mainly from the sale of products in the hyperimmune category. To determine whether to recognise revenue, the group follows the process of identifying the contract with a customer, identifying the performance obligations, determining the transaction price, allocating the transaction price to the performance obligations and recognising revenue when performance obligations are satisfied. Revenue from the sale of hyperimmune products is recognised when or as the group transfers control of the assets to the customer. There is no variable consideration or significant cost to obtain the contract. There is no warranties and no refunds. Returns are provided where this is outlined in a customer agreement. (ii) Fair value of R&D tax incentive The group's research and development (R&D) activities are eligible under an Australian government tax incentive for eligible expenditure. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. Amounts are recognised when it has been established that the conditions of the tax incentive have been met and that the expected amount can be reliably measured. For the year ended 30 June 2021, the group has included an item in other income of $306,154 (2020: $308,225) to recognise income over the year necessary to match the R&D tax incentive on a systematic basis with the costs that they are intended to compensate. Furthermore, the group subsequently received additional $50,055 in current financial year as part of the R&D claim for financial year ended 30 June 2020. (iii) Fair value of COVID-19 government assistance and R&D grants The group's other grant income is recognised when compliance with the conditions attached to the grant have been determined and the group has ascertained the grant will be received. For the year ended 30 June 2021, the group has recognised $161,600 (2020: $154,904) in the COVID-19 government assistance packages and a $74,821 (2020: Nil

Expenses

Expenses	12 Months Ended
	Jun. 30, 2021
Disclosure of expenses by nature [text block] [Abstract]
Expenses	Note 3. Expenses 30 June 30 June 30 June General and administrative expenses Accounting and audit 547,055 389,798 496,983 Bad debts 5,472 26,983 50,429 Consulting 126,215 181,474 243,508 Depreciation 43,662 44,056 5,287 Employee benefits 1,775,809 1,531,037 1,599,023 Expected credit losses (30,055 ) (3,991 ) 34,046 Insurance 341,202 469,844 307,757 Investor relations 38,568 197,839 128,415 Legal 205,722 184,382 171,145 Listing and share registry 292,113 212,236 186,013 Occupancy - 51,973 105,606 Superannuation 41,964 48,877 55,176 Travel and entertainment 1,398 91,347 159,911 Other 589,554 278,135 151,007 3,978,679 3,703,990 3,694,306 Research and development expenses Consulting 1,006,086 262,720 430,996 Project research and development 360,968 915,965 613,532 1,367,054 1,178,685 1,044,528 Selling and marketing expenses Selling 25,858 340,046 277,478 Marketing 90,652 295,261 377,427 Distribution costs 171,174 236,244 209,739 287,684 871,551 864,644

Income Tax Benefit

Income Tax Benefit	12 Months Ended
	Jun. 30, 2021
Disclosure of income tax [text block] [Abstract]
Income Tax Benefit	Note 4. Income Tax Benefit 30 June 30 June Unused tax losses for which no deferred tax asset has been recognised 44,178,579 40,018,956 Potential tax benefit 26% (2020: 27.5%) 11,486,431 11,005,213 Numerical reconciliation of income tax expense to prima facie tax payable 30 June 30 June Loss from continuing operations before income tax expense (8,384,465 ) (2,927,206 ) Tax at the Australian tax rate of 26% (2020: 27.5%) (2,179,961 ) (804,982 ) Tax effect of amounts which are not deductible (taxable) in calculating taxable income: R&D tax incentive (92,614 ) (84,762 ) Accounting expenditure subject to R&D tax incentive 212,907 194,855 Share-based payments 550,163 (146,826 ) Net impact of other amounts not deductible (taxable) 428,003 (18,678 ) Subtotal (1,081,502 ) (860,393 ) Tax losses and other timing differences for which no deferred tax asset is recognised 1,081,502 860,393 Income tax expense - -

Key Management Personnel Compen

Key Management Personnel Compensation	12 Months Ended
	Jun. 30, 2021
Disclosure of information about key management personnel [text block] [Abstract]
Key Management Personnel Compensation	Note 5. Key Management Personnel Compensation This note details the nature and amount of remuneration for each Director of Immuron Limited, and for the Key Management Personnel. The Directors of Immuron Limited during the year ended June 30, 2021 were: The following persons held office as Directors of Immuron Limited during the financial year: Dr Roger Aston, Independent Non-Executive Chairman Mr Peter Anastasiou, Executive Vice Chairman (resigned on 24 September 2021) Mr Daniel Pollock, Independent Non-Executive Director Mr Stephen Anastasiou, Independent Non-Executive Director Prof. Ravi Savarirayan, Independent Non-Executive Director The following persons held office as Key Management Personnel of Immuron Limited during the financial year ended June 30, 2021: Dr Jerry Kanellos, Chief Operating Officer and Chief Executive Officer. The aggregate compensation made to Directors and Other Key Management Personnel of the Company is set out below: 30 June 30 June 30 June A$ A$ A$ Key Management Personnel Compensation Short-term employee benefits 450,002 867,054 952,406 Other short-term benefits, including consulting services by KMP and their related entities 1,603,747 - - Post-employment benefits 27,869 29,213 32,300 Long-term benefits 8,220 3,610 3,652 Share-based payment expenses to KMP and their related entities 2,116,012 73,088 1,296,400 Total Key Management Personnel Compensation 4,205,850 972,965 2,284,758

Loss per Share

Loss per Share	12 Months Ended
	Jun. 30, 2021
Disclosure of earnings per share [text block] [Abstract]
Loss per Share	Note 6. Loss per Share 30 June 30 June 30 June A$ A$ A$ Basic/Diluted loss per share (in cents) 3.79 1.66 3.22 a) Net loss used in the calculation of basic and diluted loss per share 8,384,465 2,927,206 4,656,421 b) Weighted average number of ordinary shares outstanding during the period used in the calculation of basic and diluted loss per share 221,062,229 176,393,354 144,740,535 The Company is currently in a loss making position and thus the impact of potential issuance of shares is concluded as anti-dilutive which includes the Company’s options and warrants and convertible notes payable. Treasury shares are excluded from the calculation of weighted average number of ordinary shares.

Cash

Cash	12 Months Ended
	Jun. 30, 2021
Disclosure Of Cash Explanatory [Abstract]
Cash	Note 7. Cash 30 June 30 June A$ A$ Cash at Bank and in hand: Cash at bank and in hand 25,047,281 3,250,468 Total Cash 25,047,281 3,250,468

Trade and Other Receivables

Trade and Other Receivables	12 Months Ended
	Jun. 30, 2021
Disclosure of trade and other receivables [text block] [Abstract]
Trade and Other Receivables	Note 8. Trade and Other Receivables 30 June 30 June A$ A$ Current Trade receivables* 28,553 49,519 Loss allowance - (30,055 ) Accrued income** 306,154 308,225 Total Trade and Other Receivables 334,707 327,689 * All trade receivables are non-interest bearing. ** Primarily comprises of receivables from the Australian Tax Office in relation to R&D tax concession for the year.

Inventories

Inventories	12 Months Ended
	Jun. 30, 2021
Disclosure of inventories [text block] [Abstract]
Inventories	Note 9. Inventories 30 June 2021 30 June Current Non- Total Current Non- Total Raw materials and stores (Colostrum) - 1,266,587 1,266,587 - 1,722,349 1,722,349 Work in progress - - - 117,576 - 117,576 Finished goods (Travelan and Protectyn) 292,532 - 292,532 680,114 - 680,114 292,532 1,266,587 1,559,119 797,690 1,722,349 2,520,039

Controlled Entities

Controlled Entities	12 Months Ended
	Jun. 30, 2021
Controlled Entities [Abstract]
Controlled Entities	Note 10. Controlled Entities The Company’s subsidiaries at 30 June 2021 are set out below. Unless otherwise stated, they have share capital consisting solely of ordinary shares that are held directly by the Company, and the proportion of ownership interests held equals the voting rights held by the Company. The country of incorporation or registration is also their principal place of business. Percentage of Ownership Country of Incorporation 30 June 30 June Parent Entity: Immuron Limited Australia — — Subsidiaries of Immuron Limited: Immuron Inc. USA 100 % 100 % Anadis EPS Pty Ltd Australia 100 % 100 % IMC Canada Ltd. Canada 100 % 100 %

Trade and Other Payables

Trade and Other Payables	12 Months Ended
	Jun. 30, 2021
Disclosure of trade and other payables [text block] [Abstract]
Trade and Other Payables	Note 11. Trade and Other Payables 30 June A$ 30 June A$ Current Trade payables 106,893 157,644 Accrued expenses 625,980 210,734 Other payables 25,621 16,019 Total 758,494 384,397

Provision for Sales Returns

Provision for Sales Returns	12 Months Ended
	Jun. 30, 2021
Disclosure Of Provision For Sales Returns Explantory [Abstract]
Provision for Sales Returns	Note 12. Provision for Sales Returns Sales return provision due to the ongoing COVID-19 pandemic 2021 Carrying amount at the start of the year - Sales return provision recognised 213,024 Amounts transferred from non-current - Carrying amount at the end of the year 213,024 The sales return provision has been assessed by management based on external reports on stock held by distributors. The timing and amount of the obligation are uncertain but are expected to be settled in the next year.

Contingent liabilities and Comm

Contingent liabilities and Commitments	12 Months Ended
	Jun. 30, 2021
Contingent Liabilities [Abstract]
Contingent liabilities and Commitments	Note 13. Contingent liabilities and Commitments The group had no contingent liabilities or commitments at June 30, 2021 (2020: Nil

Leases

Leases	12 Months Ended
	Jun. 30, 2021
Disclosure of leases [text block] [Abstract]
Leases	Note 14. Leases (i) Amounts recognized in the balance sheet The balance sheet shows the following amounts relating to leases: 30 June 2021 30 June 2020 Right-of-use assets 1 Properties 19,471 58,095 19,471 58,095 Lease liabilities 2 Current 20,498 42,176 Non-current - 18,929 20,498 61,105 1. Included in the line item ‘property, plant and equipment’ in the consolidated balance sheet. 2. Included in the line items ‘other current liabilities’ and ‘other non-current liabilities’ in the consolidated balance sheet. (ii) Amounts recognized in the statement of profit or loss The statement of profit or loss shows the following amounts relating to leases: 2021 2020 Depreciation charge of right-of-use assets Properties 38,624 38,729 38,624 38,729 Interest expense (included in finance cost) 1,152 4,192 Expense relating to short-term leases (included in other expenses) - - Expense relating to leases of low-value assets that are not short-term leases (included in other expenses) - - Expense relating to variable lease payments not included in lease liabilities (included in other expenses) - - Cash paid for principal payments 40,607 41,390 The total finance cash outflow for leases in 2021 was A$1,152. The total finance cash outflow for leases in 2020 was A$4,192. (iii) The group’s leasing activities and how these are accounted for In January 2019, the group entered into a three-year commercial lease in Blackburn North. The lease is for the use of warehousing and office facilities. This lease includes an extension option for a further 3 years by written request to the landlord before 31 December 2021. There is no variability and no covenants included in the lease. Leases are recognized as a right-of-use asset and a corresponding liability at the date at which the leased asset is available for use by the group. Each lease payment is allocated between the liability and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. The right-of-use asset is depreciated over the shorter of the asset’s useful life and the lease term on a straight-line basis. Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments: ● fixed payments (including in-substance fixed payments), less any lease incentives receivable ● variable lease payment that are based on an index or a rate ● amounts expected to be payable by the lessee under residual value guarantees ● the exercise price of a purchase option if the lessee is reasonably certain to exercise that option, and ● payments of penalties for terminating the lease, if the lease term reflects the lessee exercising that option. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be determined, or the group’s incremental borrowing rate. Right-of-use assets are measured at cost comprising the following: ● the amount of the initial measurement of lease liability ● any lease payments made at or before the commencement date, less any lease incentives received ● any initial direct costs, and ● restoration costs. Payments associated with short-term leases and leases of low-value assets are recognized on a straight-line basis as an expense in profit or loss. Short-term leases are leases with a lease term of 12 months or less. Low-value assets comprise IT-equipment and small items of office furniture.

Share Capital

Share Capital	12 Months Ended
	Jun. 30, 2021
Disclosure of classes of share capital [text block] [Abstract]
Share capital	Note 15. Share capital 2021 2020 2019 2021 2020 2019 Ordinary shares Fully paid 227,246,596 178,279,566 163,215,706 88,361,303 62,426,991 60,289,875 227,246,596 178,279,566 163,215,706 88,361,303 62,426,991 60,289,875 (i) Movements in ordinary shares: Details Number of shares Total Balance at 30 June 2018 142,778,206 58,237,314 Issue at $0.16 in lieu of payment for services (2018-11-22) 1 437,500 93,678 Issue at US$0.10 pursuant to ADS public offering (2019-05-30) 2 20,000,000 2,894,238 Reclassify exercised options from reserves to share capital — 100 Transaction costs arising on representative warrants issued 3 — (110,400 ) Less: Transaction costs arising on share issues — (825,055 ) Balance at 30 June 2019 163,215,706 60,289,875 Issue at US$0.10 pursuant to ADS public offering (2019-07-19) 13,565,200 1,926,186 Issue at A$0.16 in lieu of payment for services (2019-11-12) 1 437,500 100,978 Exercise of NASDAQ Warrants (2020-06-23) 86,240 72 Exercise of representative warrants (2020-06-15, 2020-06-22) 974,920 540,062 Transaction costs arising on representative warrants issued — (55,454 ) Less: Transaction costs arising on share issues — (374,728 ) Balance at 30 June 2020 178,279,566 62,426,991 Exercise of representative warrants (2020-07-02) 5,720 - Issue at US$0.47 pursuant to ADS public offering (2020-07-24) 42,666,720 28,165,836 Issue at $0.50 on exercise of ESOP unlisted options (2020-07-24) 100,000 50,000 Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-27) 3,008,000 1,051,626 Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-29) 40,000 13,959 Transfer from reserves on exercise of ESOP unlisted options (2020-07-24) - 15,700 Transfer from reserves on exercise of NASDAQ Warrants (2020-07-27, 2020-07-29) - 1,012 Issue at A$0.08 in lieu of cash for services rendered (2020-11-13) 2,737,500 219,000 Transfer from reserves on cashless exercise of ESOP unlisted options (2021-02-09) 409,090 197,010 Less: Transaction costs arising on share issues - (3,779,831 ) Balance at 30 June 2021 227,246,596 88,361,303 Notes 1. Mr Peter (resigned 24 September 2021) and Mr Stephen Anastasiou are directors and majority shareholders of Grandlodge Capital Pty Ltd (Grandlodge). As per an agreement which commenced on 1 June 2013 and expired on 30 June 2020, Immuron Limited contracted Grandlodge on normal commercial terms and conditions to provide warehousing, distribution and invoicing services for Immuron Limited’s products for A$70,000 per annum. These fees would be payable in new fully paid ordinary shares in Immuron Limited at a set price of A$0.16 per share, representing Immuron Limited’s shares price at the commencement of the agreement. The above amount is the fair value of the equity instrument. 2. On 30 May 2019, 500,000 American Depository Shares (ADS) were issued at US$4.00 each. Each ADS is equivalent to 40 ordinary shares, i.e. 20,000,000 at US$0.10 each (A$0.1447). (ii) Ordinary shares Ordinary shares entitle the holder to participate in dividends, and to share in the proceeds of winding up the company in proportion to the number of and amounts paid on the shares held. On a show of hands every holder of ordinary shares present at a meeting in person or by proxy, is entitled to one vote, and upon a poll each share is entitled to one vote. Ordinary shares have no par value and the Company does not have a limited amount of authorized capital. (iii) Options Information relating to options, including details of options issued, exercised and lapsed during the financial year and options outstanding at the end of the reporting period, is set out in notes 15 and 18.

Other Reserves

Other Reserves	12 Months Ended
	Jun. 30, 2021
Disclosure of reserves within equity [text block] [Abstract]
Other reserves	Note 16. Other reserves The following table shows a breakdown of the consolidated statement of financial position line item ‘other reserves’ and the movements in these reserves during the year. A description of the nature and purpose of each reserve is provided below the table. Notes Share-based payments Foreign currency translation Total other reserves At 1 July 2018 3,139,625 (43,317 ) 3,096,308 Currency translation differences - 61,846 61,846 Other comprehensive income - 61,846 61,846 Transactions with owners in their capacity as owners Options and warrants issued/expensed 1,453,900 - 1,453,900 Options and warrants exercised (100 ) - (100 ) Options and warrants lapsed/expired (311,635 ) - (311,635 ) At 30 June 2019 4,281,790 18,529 4,300,319 Notes Share-based payments Foreign currency translation Total other reserves At 1 July 2019 4,281,790 18,529 4,300,319 Currency translation differences - 102,938 102,938 Other comprehensive income - 102,938 102,938 Transactions with owners in their capacity as owners Share-based payment expenses 16(iv) 73,088 - 73,088 Options and warrants issued/expensed (484,680 ) - (484,680 ) Options and warrants lapsed/expired (2,251,320 ) - (2,251,320 ) Re-valuation of options issued in prior period 16(iii) (607,000 ) - (607,000 ) At 30 June 2020 1,011,878 121,467 1,133,345 Notes Share-based payments Foreign currency translation Total other reserves At 1 July 2020 1,011,878 121,467 1,133,345 Currency translation differences - (14,953 ) (14,953 ) Other comprehensive income - (14,953 ) (14,953 ) Transactions with owners in their capacity as owners Transfer to share capital 16(iv) (73,088 ) - (73,088 ) Options and warrants issued/expensed 16(ii) 3,003,060 - 3,003,060 Options and warrants exercised 16(ii) (213,722 ) - (213,722 ) Options and warrants forfeited (368,000 ) - (368,000 ) At 30 June 2021 3,360,128 106,514 3,466,642 (i) Nature and purpose of other reserves Share-based payments The share-based payment reserve records items recognized as expenses on valuation of share options and warrants issued to key management personnel, other employees and eligible contractors. Foreign currency translation Exchange differences arising on translation of foreign controlled entities are recognized in other comprehensive income as described in note 1(d) and accumulated in a separate reserve within equity. The cumulative amount is reclassified to profit or loss when the net investment is disposed of. (ii) Movements in options and warrants: Details Notes Number of options Total Balance at 30 June 2018 72,569,180 3,139,625 Issue of ESOP unlisted options at $0.50 (2018-07-13) 1,300,000 204,100 Issue of ESOP unlisted options at $0.50 (2018-11-26) 2,000,000 164,400 Lapse of ESOP unlisted options at $0.50 (2018-10-01) (1,050,000 ) (98,385 ) Issue of ESOP unlisted options at $0.50 (2019-02-11) 5,000,000 975,000 Lapse of unlisted options at $0.57 (2019-02-24) (1,000,000 ) (185,601 ) Lapse of unlisted options at $1.892 (2019-02-28) (15,380 ) (1,173 ) Lapse of unlisted options at $0.30 (2019-05-28) (140,056 ) (13,390 ) Reclassify exercised options from reserves to share capital - (100 ) Reclassify lapsed options from reserves to accumulated losses - (13,086 ) Issue of representative warrants (2019-05-23) 1 800,000 110,400 Balance at 30 June 2019 79,463,744 4,281,790 Re-valuation of options issued in prior period (2019-11-06) 16(iii) - (607,000 ) Issue of representative warrants (2019-07-16) 542,600 55,454 Lapse of unexercised options at $0.50 (2019-11-27) (7,625,532 ) (2,086,920 ) Lapse of unexercised options at $0.55 (2019-11-30) (25,289,894 ) - Lapse of unexercised options at $0.50 (2020-06-30) (2,000,000 ) (164,400 ) Exercise of NASDAQ Warrants at US$10 per 40 options (2020-06-23) (218,800 ) (72 ) Exercise of representative warrants (2020-06-15, 2020-06-22) (2,065,000 ) (540,062 ) Balance at 30 June 2020 42,807,118 938,790 Exercise of representative warrants (2020-07-2) (9,640 ) - Exercise of ESOP unlisted options at $0.50 (2020-07-24) (100,000 ) (15,700 ) Exercise of NASDAQ Warrants at US$10 per 40 options (2020-07-27, 2020-07-29) (3,048,000 ) (1,012 ) Lapse of unexercised options (2020-09-25) (5,000,000 ) (368,000 ) Issue of representative warrants at US$23.44 per 40 options (2020-07-24) 2,560,000 1,032,960 Issue of ESOP unlisted options at $0.12 (2020-10-29) 9,000,000 1,970,100 Cashless exercise of ESOP unlisted options at $0.12 (2021-02-09) (900,000 ) (197,010 ) Reclassify share-based payments expenses from reserves to share capital 16(iv) - (73,088 ) Balance at 30 June 2021 45,309,478 3,360,128 On 13 July 2018, the Company issued Dr. Jerry Kanellos, Chief Operating Officer of Immuron Limited, 1,000,000 unlisted options exercisable at $0.50 on or before 1 July 2021. On 26 November 2018, the Company issued Mr. Richard J. Berman, a Non-Executive Director of Immuron Limited, 2,000,000 unlisted options exercisable at $0.50 on or before June 30, 2021. During the 2019 annual general meeting, the shareholders approved the issuance of the options to Richard Berman. On 11 February 2019, the Company issued Dr. Gary S. Jacob 5,000,000 unlisted options exercisable at $0.50. These options were subsequently forfeited on September 25, 2020, being 6 months after his resignation. Given the shareholders' approval at the AGM held on 29 October 2020, a total of 9,000,000 ESOP Options were issued to directors on 13 November 2020. (iii) Revaluation of options issued in prior period Options granted to Dr Gary Jacob on 11 February 2019 and valued at $975,000 in the 30 June 2019 financials were subject to shareholder approval. In line with IFRS 2, these were re-measured at grant date 6 November 2019 after being approved by shareholders with a value of $368,000, being a revaluation of $607,000 in the 30 June 2020 financials. (iv) Share-based payment expenses Due to the ongoing crisis of COVID-19, the groups directors decided to forgo cash payments of their director fees from 1 April 2020 to 31 December 2020 and instead receive shares of that value. In prior year, no shares were issued to directors, however the expense of the shares owed to them was A$73,088. As at 30 June 2021, shares have been issued to directors given the shareholders' approval at the AGM held on 29 October 2020.

Segment Reporting

Segment Reporting	12 Months Ended
	Jun. 30, 2021
Disclosure of entity's operating segments [text block] [Abstract]
Segment Reporting	Note 17. Segment Reporting Description of segments and principal activities The group has identified its operating segments based on the internal reports that are reviewed and used by the executive management team in assessing performance and determining the allocation of resources. Management considers the business from both a product and a geographic perspective and has identified two reportable segments: Research and development (R&D): income and expenses directly attributable to the group’s R&D projects performed in Australia, Israel and United States. Hyperimmune products: income and expenses directly attributable to Travelan and Protectyn activities which occur in Australia, the United States, Canada and the rest of the world. Financial breakdown The segment information for the reportable segments for the year ended June 30, 2021 is as follows: Research and development Hyperimmune products Other Total 2021 A$ A$ A$ A$ Hyperimmune products revenue - 145,776 - 145,776 Cost of sales of goods - (51,071 ) - (51,071 ) Gross profit - 94,705 - 94,705 Other income 431,030 24,480 161,600 617,110 Other gains/(losses) – net - (759,765 ) (582,528 ) (1,342,293 ) General and administrative expenses - - (3,978,679 ) (3,978,679 ) Share-based payment expenses - - (2,116,013 ) (2,116,013 ) Research and development expenses (1,367,054 ) - - (1,367,054 ) Selling and marketing expenses - (287,684 ) - (287,684 ) Operating profit/(loss) (936,024 ) (928,264 ) (6,515,620 ) (8,379,908 ) Finance income - - 9,204 9,204 Finance costs - - (13,761 ) (13,761 ) Income tax expense - - - - Profit/(loss) for the year (936,024 ) (928,264 ) (6,520,177 ) (8,384,465 ) Assets Segment assets 306,154 1,587,672 25,159,280 27,053,106 Total assets 306,154 1,587,672 25,159,280 27,053,106 Liabilities Segment liabilities 243,565 284,657 629,827 1,158,049 Total liabilities 243,565 284,657 629,827 1,158,049 The segment information for the reportable segments for the year ended June 30, 2020 is as follows: Research and development Hyperimmune products Other Total 2020 A$ A$ A$ A$ Hyperimmune products revenue - 2,518,566 - 2,518,566 Cost of sales of goods - (688,836 ) - (688,836 ) Gross profit - 1,829,730 - 1,829,730 Other income 308,225 10,545 154,904 473,674 Other gains/(losses) – net - - 11,335 11,335 General and administrative expenses - - (3,170,078 ) (3,170,078 ) Research and development expenses (1,178,685 ) - - (1,178,685 ) Selling and marketing expenses - (871,551 ) - (871,551 ) Operating profit/(loss) (870,460 ) 968,724 (3,003,839 ) (2,905,575 ) Finance income - - - - Finance costs - - (21,631 ) (21,631 ) Income tax expense - - - - Profit/(loss) for the year (870,460 ) 968,724 (3,025,470 ) (2,927,206 ) Assets Segment assets 308,225 2,539,503 3,354,435 6,202,163 Total assets 308,225 2,539,503 3,354,435 6,202,163 Liabilities Segment liabilities 101,092 30,377 426,781 558,250 Total liabilities 101,092 30,377 426,781 558,250 The segment information for the reportable segments for the year ended June 30, 2019 is as follows: Research and development Hyperimmune products Other Total 2019 A$ A$ A$ A$ Hyperimmune products revenue - 2,387,426 - 2,387,426 Cost of sales of goods - (667,371 ) - (667,371 ) Gross profit - 1,720,055 - 1,720,055 Other income 531,005 1,045 - 532,050 Other gains/(losses) – net - (13,394 ) 51,807 38,413 General and administrative expenses - - (5,037,806 ) (5,037,806 ) Research and development expenses (1,044,528 ) - - (1,044,528 ) Selling and marketing expenses - (864,644 ) - (864,644 ) Operating profit/(loss) (513,523 ) 843,062 (4,985,999 ) (4,656,460 ) Finance income - - 39 39 Profit/(loss) for the year (513,523 ) 843,062 (4,985,960 ) (4,656,421 ) Assets Segment assets 531,828 2,705,330 5,324,489 8,561,647 Total assets 531,828 2,705,330 5,324,489 8,561,647 Liabilities Segment liabilities 221,520 191,836 797,155 1,210,511 Total liabilities 221,520 191,836 797,155 1,210,511 Information on geographical regions: The group derives revenue from the transfer of hyperimmune products at a point in time in the following major product lines and geographical regions: Travelan Protectyn Australia United States Other Australia Other Total 2021 A$ A$ A$ A$ A$ A$ Hyperimmune products revenue 1 (10,308 ) 4,264 101,639 50,181 - 145,776 Revenue from external customers (10,308 ) 4,264 101,639 50,181 - 145,776 1. Returns are provided where outlined in a customer’s agreement. Travelan Protectyn Australia United States Other Australia Other Total 2020 A$ A$ A$ A$ A$ A$ Hyperimmune products revenue 1,240,393 926,325 301,915 49,933 - 2,518,566 Revenue from external customers 1,240,393 926,325 301,915 49,933 - 2,518,566 Travelan Protectyn Australia United States Other Australia Other Total 2019 A$ A$ A$ A$ A$ A$ Segment revenue 1,162,628 1,016,468 149,283 58,683 364 2,387,426 Revenue from external customers 1,162,628 1,016,468 149,283 58,683 364 2,387,426 Information on major customers: During the years ended June 30, 2021, 2020 and 2019, the Company had the following major customers in the hyperimmune product segment with revenues amounting to 10 percent or more of total group revenues: 2021 A$ 2020 A$ 2019 A$ Customer A 41,040 - - Customer B 27,563 - - Customer C 25,319 - - Customer D 23,214 462,490 611,920 Customer E 22,886 - - Customer F - 442,916 228,661 Customer G - 438,065 659,637 Customer H - 327,559 266,111 Customer I - 227,952 249,522 140,022 1,898,982 2,015,851

Cash Flow Information

Cash Flow Information	12 Months Ended
	Jun. 30, 2021
Disclosure Of Cash Flow Information Explanatory [Abstract]
Cash Flow Information	Note 18. Cash Flow Information (a) Reconciliation of cash flow from operations with loss after income tax 30 June 30 June 30 June Net Loss for the Year (8,384,465 ) (2,927,206 ) (4,656,421 ) Adjustments for Depreciation expense 43,662 44,056 5,287 Distribution costs - 70,000 70,000 Expected credit losses (30,055 ) (3,991 ) 34,046 Finance costs 13,761 21,631 — Finance income (9,204 ) - (39 ) Leave provision expense 53,610 19,717 4,580 Share-based payments (income)/expenses 2,116,013 (533,912 ) 1,343,500 Unrealized net foreign currency gains 592,243 (18,883 ) (62,015 ) Change in operating assets and liabilities: Add decrease in trade and other receivables 23,037 641,236 680,337 Add (increase) / decrease in inventories 960,920 (113,635 ) 263,365 Add (increase) / decrease in other operating assets (45,065 ) 16,096 92,510 Add (decrease) / increase in trade and other payables 586,796 (362,437 ) 426,271 (4,078,747 ) (3,147,328 ) (1,798,579 ) (b) Non-cash financing and investing activities See note 19 for details regarding issues of options to employees and for details surrounding the issue of shares to suppliers.

Share-based Payments

Share-based Payments	12 Months Ended
	Jun. 30, 2020
Disclosure of share-based payment arrangements [text block] [Abstract]
Share-based Payments	Note 19. Share-based Payments a) Executive share and option plan The establishment of the ‘executive share and option plan’ (ESOP) was approved by shareholders at the 2017 annual general meeting. The plan is designed to provide long-term incentives for executives (including directors) to deliver long-term shareholder returns. Participation in the plan is at the board’s discretion and no individual has a contractual right to participate in the plan or to receive any guaranteed benefits. Options issued to Dr Gary Jacob expire within 6 months upon his resignation without good reason or termination. All other options issued expire upon departure from the company if they are determined to be a ‘bad leaver’. Set out below are summaries of all listed and unlisted options, including those issued under ESOP: 2021 2020 2019 Average exercise price per share option (A$) Number of options Average exercise price per share option (A$) Number of options Average exercise price per share option (A$) Number of options As at 1 July 0.40 42,807,118 0.46 79,463,744 0.45 72,569,180 Granted during the year 0.28 11,560,000 0.18 542,600 0.47 9,100,000 Exercised during the year 0.23 (4,057,640 ) 0.18 (424,840 ) - - Forfeited/lapsed during the year 0.50 (5,000,000 ) 0.52 (36,774,386 ) 0.53 (2,205,436 ) As at 30 June 0.31 45,309,478 0.40 42,807,118 0.46 79,463,744 Vested and exercisable at 30 June 0.31 45,309,478 0.40 42,807,118 0.46 79,463,744 Share options outstanding at the end of the year have the following expiry date and exercise prices: Expiry Exercise Share options Share options Grant date (A$ unless stated otherwise) 30 June 30 June 2012-06-29 2021-11-30 1.944 14,493 14,493 2012-06-29 2022-01-17 1.876 29,668 29,668 2017-06-13 (warrants) 2022-06-13 USD 0.25 24,493,200 27,541,200 2018-03-15 2023-03-15 0.468 7,897,647 7,897,647 2017-06-09 (warrants) 2022-06-08 USD 0.3125 198,240 198,240 2018-03-15 2023-03-15 0.585 526,510 526,510 2019-05-23 (warrants) 2024-05-23 USD 0.125 173,600 181,600 2019-07-16 (warrants) 2024-07-16 USD 0.125 116,120 117,760 2018-07-13 2021-07-01 0.500 1,200,000 1,300,000 2019-11-06 2024-02-10 0.500 - 5,000,000 2020-10-29 2024-04-14 0.12 8,100,000 - 2020-07-24 (warrants) 2025-07-21 USD 0.5859 2,560,000 - Total 45,309,478 42,807,118 Weighted average remaining contractual life of options outstanding at end of period 1.58 2.28 (i) Fair value of options granted The assessed fair value of options at grant date was determined using the Black-Scholes option pricing model that takes into account the exercise price, term of the option, security price at grant date and expected price volatility of the underlying security, the expected dividend yield, the risk-free interest rate for the term of the security and certain probability assumptions. The model inputs for options granted under ESOP during the year ended June 30, 2021 included: Grant date Expiry date Exercise price No. of options Share price at grant date Expected volatility Dividend yield Risk- free interest rate Fair value 2020-07-24 2025-07-21 0.83 2,560,000 0.50 127.93 % 0.00 % 0.43 % 0.4035 2020-10-29 2024-04-14 0.12 9,000,000 0.25 142.70 % 0.00 % 0.13 % 0.2189 11,560,000 The model inputs for options granted under ESOP during the year ended June 30, 2020 included: Grant date Expiry date Exercise No. of Share price at grant date Expected Dividend Risk- free Fair value 2019-11-06 2024-02-10 0.50 5,000,000 0.15 98 0.00 % 0.88 % 0.0736 5,000,000 The model inputs for options granted under ESOP during the year ended June 30, 2019 included: Grant date Expiry date Exercise No. of Share price at grant date Expected Dividend Risk- free Fair value 2018-07-13 2021-07-01 0.50 1,300,000 0.32 92.00 % 0.00 % 2.09 % 0.1570 2018-11-26 2020-06-30 0.50 2,000,000 0.34 92.00 % 0.00 % 2.02 % 0.0822 2019-02-11 2024-02-11 0.50 5,000,000 0.29 100.00 % 0.00 % 1.69 % 0.1950 8,300,000 The expected life of the options is based on historical data and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility is indicative of future trends, which may also not necessarily be the actual outcome. b) Expenses arising from share-based payment transactions Total expenses arising from share-based payment transactions recognized during the period were as follows: 2021 2020 1 2019 Options issued under ESOP 1,970,100 (607,000 ) 1,343,500 Share-based payments to directors 2 145,913 73,088 - 2,116,013 (533,912 ) 1,343,500 1. Options granted to a former managing director on 11 February 2019 and valued at $975,000 in the 30 June 2019 financials were subject to shareholder approval. In line with IFRS 2, these were re-measured at grant date 6 November 2019 after being approved by shareholders with a value of $368,000, being a revaluation of $607,000 in the 30 June 2020 financials. 2. Due to the ongoing crisis of COVID-19, the groups directors decided to forgo cash payments of their director fees and instead receive shares of that value. As at 30 June 2021, shares have been issued to directors for the director fees of $145,913 incurred during the financial year ended 30 June 2021 and $73,088 incurred during the financial year ended 30 June 2020, given the shareholders' approval at the AGM held on 29 October 2020.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2021
Disclosure of related party [text block] [Abstract]
Related Party Transactions	Note 20. Related Party Transactions (a) Subsidiaries Interests in subsidiaries are set out in note 10. (b) Transactions with other related parties The following transactions occurred with related parties: 2021 2020 2019 Amounts settled in cash or shares for goods and services Purchases of various goods and services from entities controlled by key management personnel (i) 110,607 142,347 147,636 (i) Purchases from entities controlled by key management personnel The group acquired the following goods and services from entities that are controlled by members of the group’s key management personnel: ● rental of an office suite (Wattle Laboratories Pty Ltd); and Effective January 2016, we executed a Lease Agreement with Wattle Laboratories Pty Ltd, (“Wattle”), an entity part-owned and operated by our non-executive directors, Mr. Peter Anastasiou (a director resigned on 24 September 2021) and Mr. Stephen Anastasiou, whereby we lease part of their Blackburn office facilities for our operations at a rental rate of A$38,940 per year, payable in monthly installments. The rental agreement is subject to annual rental increases, and effective January 2017, the annual rent was increased to A$39,525. The lease is for a three-year term with an additional three-year option period. The lease may be terminated by either party upon six months’ written notice. During the fiscal years ended June 30, 2019, 2020 and 2021, we paid Wattle A$53,958, A$41,369 and A$40,607 (excluding Goods and Services Tax), respectively. The lease was renewed, commencing January 1, 2019 for three years. ● warehousing, distribution and invoicing services (Grandlodge Capital Pty Ltd). Grandlodge Capital Pty Ltd is an entity part-owned and operated by our non-executive director Mr. Stephen Anastasiou. Mr. Peter Anastasiou (a director resigned on 24 September 2021) and Mr. David Plush are also owners of Grandlodge, and its associated entities. Commenced on June 1, 2013, Grandlodge provides warehousing, distribution and invoicing services for our products for A$70,000 per year. The terms of the agreement were to have fees payable in new fully paid ordinary shares in Immuron Limited as a set price of A$0.16 per share. The fair value of the equity instrument has been assessed and accounted for in accordance with IFRS 2 Share Based Payments in the 2020 financial statements. During the 2020 financial year, the fees of A$100,978 equivalent were repaid by issuance of 437,500 ordinary shares based on their fair value. During the 2019 financial year, the fees of A$93,678 equivalent were repaid by issuance of 437,500 ordinary shares based on based on their fair value. Grandlodge is reimbursed in cash for all reasonable costs and expenses incurred in accordance with their scope of works under the oral agreement, unless both Grandlodge and we agree to an alternative method of payment. The oral agreement may be terminated by either party upon providing the other party with 30 days written notice of the termination of the agreement. A new agreement commenced on July 1, 2020. Grandlodge was contracted on commercial terms to provide warehousing, distribution and invoicing services for Immuron's products for $70,000 per annum. The terms of the agreement were to have fees payable in cash. Aggregate amounts of each of the above types of other transactions with key management personnel of Immuron Limited: 2020 2020 2019 Amounts settled in cash or shares during the period Rental of an office suite from Wattle Laboratories Pty Ltd 40,607 41,369 53,958 Services rendered by Grandlodge Capital Pty Ltd 70,000 100,978 93,678 110,607 142,347 147,636 (c) Outstanding balances arising from sales/purchases of goods and services The following balances are outstanding at the end of the reporting period in relation to transactions with related parties: 2021 A$ 2020 A$ 2019 A$ Current payables (purchases of goods and services) Entities controlled by key management personnel 70,000 - -

Financial Risk Management Objec

Financial Risk Management Objectives and Policies	12 Months Ended
	Jun. 30, 2021
Disclosure of financial risk management [text block] [Abstract]
Financial Risk Management Objectives and Policies	Note 21. Financial Risk Management Objectives and Policies This note explains the Group’s exposure to financial risks and how these risks could affect the Group’s future financial performance. The Group’s risk management is predominantly controlled by the Board. The Board monitors the Group’s financial risk management policies and exposures and approves substantial financial transactions. It also reviews the effectiveness of internal controls relating to market risk, credit risk and liquidity risk. Risk Management Policy The Board is responsible for overseeing the establishment and implementation of the risk management system, and reviews and assesses the effectiveness of the Company’s implementation of that system on a regular basis. The Board and Senior Management identify the general areas of risk and their impact on the activities of the Company, with Management performing a regular review of: Ø the major risks that occur within the business; the degree of risk involved; Ø the current approach to managing the risk; and Ø if appropriate, determine: ○ any inadequacies of the current approach; and ○ possible new approaches that more efficiently and effectively address the risk. Management report risks identified to the Board through the monthly Operations Report. The Company seeks to ensure that its exposure to undue risk which is likely to impact its financial performance, continued growth and survival is minimised in a cost effective manner. (a) Market risk Foreign exchange risk The Group undertakes certain transactions denominated in foreign currency and is exposed to foreign currency risk through foreign exchange rate fluctuations. Foreign exchange rate risk arises from financial assets and financial liabilities denominated in a currency that is not the group's functional currency. Exposure to foreign currency risk may result in the fair value of future cash flows of a financial instrument fluctuating due to the movement in foreign exchange rates of currencies in which the group holds financial instruments which are other than the Australian dollar (AUD) functional currency of the group including United States dollar (USD), Canadian dollar (CAD) and Israeli Shekel (ILS). This risk is measured using sensitivity analysis and cash flow forecasting. The cost of hedging at this time outweighs any benefits that may be obtained. Exposure The Group’s exposure to foreign currency risk at the end of the reporting period, expressed in Australian dollars, was as follows: 2021 2020 USD CAD USD CAD ILS Cash and cash equivalents 2,742,688 108,688 2,954,589 107,605 - Trade receivables 23,801 - 45,591 - - Trade payables 18,556 43,466 29,946 1,923 41,771 Total exposure 2,785,045 152,154 3,030,126 109,528 41,771 Sensitivity As shown in the table above, the Group is primarily exposed to changes in USD/AUD exchange rates. The sensitivity of profit or loss to changes in the exchange rates arises mainly from USD denominated financial instruments. The impact on other components of equity arises from the translation of foreign subsidiary financial statements into AUD. The Group has conducted a sensitivity analysis of its exposure to foreign currency risk. The Group is currently materially exposed to the United States dollar (USD). The sensitivity analysis is conducted on a currency-by-currency basis using the sensitivity analysis variable, which is based on the average annual movement in exchange rates over the past five years at year-end spot rates. The variable for each currency the group is materially exposed to is listed below: ● USD: 4.9% (2020: 3.3%) Impact on loss for Impact on other components 2021 2020 2021 2020 USD/AUD exchange rate – change by 4.9% (2020: 3.3%) 136,467 99,994 5,219 4,035 * Holding all other variables constant Loss is more sensitive to movements in the AUD/USD exchange rates in 2021 than 2020 because of the increased amount of USD denominated cash and cash equivalents and the increased variability of the AUD/USD exchange rate. Equity is more sensitive to movements in the AUD/USD exchange rates in 2021 than 2020 because of the increased size of the foreign currency translation reserve for the subsidiary with USD functional currency. The group's exposure to other foreign exchange movements is not material. (b) Credit risk Exposure to credit risk relating to financial assets arises from the potential non-performance by counterparties of contract obligations that could lead to a financial loss to the group. (i) Risk management Credit risk is managed through the maintenance of procedures (such as the utilisation of systems for the approval, granting and renewal of credit limits, regular monitoring of exposures against such limits and monitoring the financial stability of significant customers and counterparties), ensuring to the extent possible that customers and counterparties to transactions are of sound credit worthiness. Such monitoring is used in assessing receivables for impairment. Credit terms are normally 30 days from the invoice date. Risk is also minimised through investing surplus funds in financial institutions that maintain a high credit rating. (ii) Security For some trade receivables the group may obtain security in the form of guarantees, deeds of undertaking or letters of credit which can be called upon if the counterparty is in default under the terms of the agreement. (iii) Impairment of financial assets The group has one type of financial asset subject to the expected credit loss model: ● trade receivables for sales of inventory While cash and cash equivalents are also subject to the impairment requirements of IFRS 9, the identified impairment loss was immaterial. Trade receivables The group applies the IFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables. To measure the expected credit losses, trade receivables assets have been grouped based on shared credit risk characteristics and the days past due. The expected loss rates are based on the payment profiles of sales over a period of 60 months before June 30, 2021 and the corresponding historical credit losses experienced within this period. The historical loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the customers to settle the receivables. On that basis, the loss allowance as at June 30, 2021 was determined as follows for trade receivables: Days past due Current 1-30 31-60 61-90 91-120 121+ Total 30 June 2021 A$ A$ A$ A$ A$ A$ A$ Expected credit loss rate 0.00 % 0.00 % 13.07 % 21.88 % 34.09 % 53.58 % Gross carrying amount 23,801 4,752 - - - - 28,553 Loss allowance - - - - - - - On that basis, the loss allowance as at June 30, 2020 was determined as follows for trade receivables: Days past due 30 June 2020 Current 1-30 31-60 61-90 91-120 121+ Total Expected credit loss rate 0.60 % 8.06 % 0.00 % 23.35 % 38.30 % 100.00 % Gross carrying amount 2,820 1,055 - 14,476 7,447 23,721 49,519 Loss allowance 17 85 - 3,380 2,852 23,721 30,055 Trade receivables are written off when there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, amongst others, the failure of a debtor to engage in a repayment plan with the group, and a failure to make contractual payments for a period of greater than 121 days past due. Impairment losses on trade receivables are presented as net impairment losses within operating profit. Subsequent recoveries of amounts previously written off are credited against the same line item. Previous accounting policy for impairment of trade receivables In the prior year, the impairment of trade receivables was assessed based on the incurred loss model. Individual receivables which were known to be uncollectible were written off by reducing the carrying amount directly. The other receivables were assessed collectively to determine whether there was objective evidence that an impairment had been incurred but not yet been identified. For these receivables the estimated impairment losses were recognized in a separate provision for impairment. The Group considered that there was evidence of impairment if any of the following indicators were present: ● significant financial difficulties of the debtor; ● probability that the debtor will enter bankruptcy or financial reorganization; and ● default or late payments (more than 121 days overdue). Receivables for which an impairment provision was recognized were written off against the provision when there was no expectation of recovering additional cash. (c) Liquidity risk Liquidity risk arises from the possibility that the group might encounter difficulty in settling its debts or otherwise meeting its obligations related to financial liabilities. The group manages this risk through the following mechanisms: ● preparing forward looking cash flow analyses in relation to its operating, investing and financing activities; ● obtaining funding from a variety of sources; ● maintaining a reputable credit profile; ● managing credit risk related to financial assets; ● investing cash and cash equivalents and deposits at call with major financial institutions; and ● comparing the maturity profile of financial liabilities with the realisation profile of financial assets. Maturities of financial liabilities The tables below analyze the group’s financial liabilities into relevant maturity groupings based on their contractual maturities. The amounts disclosed in the table are the contractual discounted cash flows. Contractual maturities of financial liabilities Less than 6 months 6 - 12 months Between 1 and 2 years Between 2 and 5 years Over 5 years Total contractual cash flows Carrying amount (assets)/ liabilities At 30 June 2021 A$ A$ A$ A$ A$ A$ A$ Trade and other payables 132,514 - - - - 132,514 132,514 Lease liabilities 20,498 - - - - 20,498 20,498 Total 153,012 - - - - 153,012 153,012 At 30 June 2020 Trade and other payables 173,663 - - - - 173,663 173,663 Lease liabilities 20,890 21,286 21,286 - - 63,462 63,462 Total 194,553 21,286 21,286 - - 237,125 237,125

Events occurring after the Repo

Events occurring after the Reporting Date	12 Months Ended
	Jun. 30, 2021
Disclosure of events after reporting period [text block] [Abstract]
Events occurring after the Reporting Date	Note 22. Events occurring after the Reporting Date In May 2021, Immuron identified a transformational COVID-19 asset, for which it entered a binding contract to acquire. The company’s securities were placed in suspension by the Australian Securities Exchange (ASX) until the company met the requirements set out by the Exchange. Unfortunately, after filing an ASX In-Principal Advice Application and subsequent lengthy discussions and exchanges with the ASX, Immuron was unable to satisfy the ASX that the combined group, following the proposed acquisition, would meet the requirements of the Listing Rules. Ultimately the ASX has an absolute discretion whether to approve such a major acquisition. Immuron is now unable to satisfy the pre-conditions for this proposed acquisition due to the expiration of the existing contractual timetable and will not proceed with the proposed acquisition in its present form. On 23 September 2021, as a result of the company not proceeding with the major transaction the ASX has lifted the suspension and the company's securities have now re-commenced trading on the ASX and NASDAQ official list. On 24 September 2021, Mr Peter Anastasiou resigned as a director of the company. No other matter or circumstance has occurred subsequent to period end that has significantly affected, or may significantly affect, the operations of the group, the results of those operations or the state of affairs of the group or economic entity in subsequent financial years.

Company Details

Company Details	12 Months Ended
	Jun. 30, 2021
Disclosure Of Company Details Explanatory [Abstract]
Company Details	Note 23. Company Details The registered office of the Company is: Level 3, 62 Lygon Street, Carlton, Victoria, Australia 3053. The principal place of business of the Company is: Unit 10, 25-37 Chapman Street, Blackburn, Victoria, Australia 3130.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of preparation	(a) Basis of preparation These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board and the Corporations Act 2001 (i) Compliance with IFRS The consolidated financial statements of the Immuron Limited group also comply with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). (ii) Historical cost convention The financial statements have been prepared on a historical cost basis. (iii) Significant estimates and judgements Going concern The group is in a position to meet future commitments in the current business cycle and pay its debts as and when they fall due. Furthermore, the group is able to progress its research and development programs for at least the next 12 months. The annual report has been prepared on a going concern basis. Accordingly, the annual report does not include adjustments relating to the recoverability and classification of recorded asset amounts, or the amounts and classification of liabilities that might be necessary should the group not continue as a going concern. COVID-19 Judgement has been exercised in considering the impacts that the Coronavirus (COVID-19) pandemic has had, or may have, on the group based on known information. This consideration extends to the nature of the products and services offered, customers, supply chain, staffing and geographic regions in which the group operates. Sales of Travelan have significantly dropped from March 2020 and as at reporting date it is unknown the prolonged effect that COVID-19 will continue to have on sales. This note provides a list of the significant accounting policies adopted in the preparation of these consolidated financial statements to the extent they have not already been disclosed in the other notes above. These policies have been consistently applied to all the years presented, unless otherwise stated. The financial statements are for the group consisting of Immuron Limited and its subsidiaries. (iv) New standards and interpretations not yet adopted There are no standards that are not yet effective and that would be expected to have a material impact on the Company in the current or future reporting years and on foreseeable future transactions. (v) Revision of immaterial error During the year ended June 2020 the following immaterial error corrections were identified. Representative warrants Immuron Limited raised capital in June 2017 and May 2019, representative warrants were included as part of these public offerings. These were not identified and accounted for at the time of these capital raisings. Management has undertaken an assessment of the impact of this and concluded this to be an immaterial error. This has been corrected in the prior year by restating prior period financial statements presented and the related notes included herein to include the representative warrants. Reserves as of 30 June 2017 has been revised to increase by A$489,586 for the June 2017 representative warrants (1,220,000 options) with a corresponding decrease in share capital of the same amount. The impact of the 2017 revision has been also reflected in the 30 June 2018 and 30 June 2019 years presented. Reserves as of 30 June 2019 has been revised to increase by A$110,400 for the May 2019 representative warrants (800,000 options) with a corresponding decrease in share capital of the same amount. Summary of significant accounting policies The following is a summary of the material accounting policies adopted by the Company in the preparation of the financial report. The accounting policies have been consistently applied, unless otherwise stated.
Principles of consolidation	(b) Principles of consolidation (i) Subsidiaries Subsidiaries are all entities (including structured entities) over which the group has control. The group controls an entity when the group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the group. They are deconsolidated from the date that control ceases. The acquisition method of accounting is used to account for business combinations by the group. Intercompany transactions, balances and unrealized gains on transactions between group companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the group.
Segment reporting	(c) Segment reporting Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. This has been identified as the executive management team consisting of the CEO and COO.
Foreign currency translation	(d) Foreign currency translation (i) Functional and presentation currency Items included in the financial statements of each of the group’s entities are measured using the currency of the primary economic environment in which the entity operates (‘the functional currency’). The consolidated financial statements are presented in Australian dollar (“A$” or “$”), which is Immuron Limited’s functional and presentation currency. (ii) Transactions and balances Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates are generally recognized in profit or loss. Foreign exchange gains and losses that relate to borrowings are presented in the consolidated statement of profit or loss and other comprehensive income, within finance costs. All other foreign exchange gains and losses are presented in the consolidated statement of profit or loss and other comprehensive income on a net basis within other gains/(losses). Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. For example, translation differences on non-monetary assets and liabilities such as equities held at fair value through profit or loss are recognized in profit or loss as part of the fair value gain or loss and translation differences on non-monetary assets such as equities classified as at fair value through other comprehensive income are recognized in other comprehensive income. (iii) Group companies The results and financial position of foreign operations (none of which has the currency of a hyperinflationary economy) that have a functional currency different from the presentation currency are translated into the presentation currency as follows: ● assets and liabilities for each consolidated balance sheet presented are translated at the closing rate at the date of that consolidated balance sheet; ● income and expenses for each consolidated statement of profit or loss and consolidated statement of profit or loss and other comprehensive income are translated at average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions); and ● all resulting exchange differences are recognized in other comprehensive income. On consolidation, exchange differences arising from the translation of any net investment in foreign entities, and of borrowings and other financial instruments designated as hedges of such investments, are recognized in other comprehensive income. When a foreign operation is sold or any borrowings forming part of the net investment are repaid, the associated exchange differences are reclassified to profit or loss, as part of the gain or loss on sale.
Revenue recognition	(e) Revenue recognition (i) Sale of hyperimmune products Revenue arises mainly from the sale hyperimmune products. To determine whether to recognize revenue, the group follows the process of identifying the contract with a customer, identifying the performance obligations, determining the transaction price, allocating the transaction price to the performance obligations and recognising revenue when performance obligations are satisfied. Revenue from the sale of hyperimmune products is recognized when or as the group transfers control of the assets to the customer. There is no variable consideration or significant cost to obtain the contract. There are no warranties and no refunds. Returns are provided where this is outlined in a customer agreement. (ii) Financing components The group does not expect to have any contracts where the period between the transfer of the promised goods or services to the customer and payment by the customer exceeds one year. As a consequence, the group does not adjust any of the transaction prices for the time value of money.
Government grants	(f) Government grants Grants from the government are recognized at their fair value where there is a reasonable assurance that the grant will be received and the group will comply with all attached conditions. Fair value of other grants The group’s other grant income consists of grants received by the group with relation to COVID-19. Grants are recognized as other income when the group is reasonable assured that it will comply with the conditions attaching to it and the grant will be received. For the year ended 30 June 2020, the group has recognized A$154,904 in assistance packages.
Income tax	(g) Income tax The income tax expense or credit for the period is the tax payable on the current period’s taxable income based on the applicable income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses. The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the company and its subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities. Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, deferred tax liabilities are not recognized if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. Deferred tax assets are recognized only if it is probable that future taxable amounts will be available to utilize those temporary differences and losses. Current and deferred tax is recognized in profit or loss, except to the extent that it relates to items recognized in other comprehensive income or directly in equity. In this case, the tax is also recognized in other comprehensive income or directly in equity, respectively.
AASB Interpretation 23 Uncertainty over Income Tax Treatments	(h) AASB Interpretation 23 Uncertainty over Income Tax Treatments Interpretation 23 requires the assessment of whether the effect of uncertainty over income tax treatments should be included in the determination of taxable profit (tax loss), tax bases, unused tax losses, unused tax credits and tax rates. The Interpretation outlines the requirements to determine whether an entity considers uncertain tax treatments separately, the assumptions an entity makes about the examination of tax treatments by taxation authorities, how an entity determines taxable profit (tax loss), tax bases, unused tax losses, unused tax credits and tax rates and how an entity considers changes in facts and circumstances. The group has adopted Interpretation 23 from 1 July 2019, based on an assessment of whether it is ‘probable’ that a taxation authority will accept an uncertain tax treatment. This assessment takes into account that for certain jurisdictions in which the group operates, a local tax authority may seek to open a group’s books as far back as inception of the group. Where it is probable, the group has determined tax balances consistently with the tax treatment used or planned to be used in its income tax filings. Where the group has determined that it is not probable that the taxation authority will accept an uncertain tax treatment, the most likely amount or the expected value has been used in determining taxable balances (depending on which method is expected to better predict the resolution of the uncertainty). There has been no impact from the adoption of Interpretation 23 in this reporting period.
Leases	(i) Leases
Impairment of assets	(j) Impairment of assets An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period.
Cash and cash equivalents	(k) Cash and cash equivalents For the purpose of presentation in the consolidated statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities in the consolidated balance sheet.
Trade receivables	(l) Trade receivables Trade receivables are recognized initially at fair value and subsequently measured at amortised cost using the effective interest method, less loss allowance. See note 21(b) for a description of the group’s impairment policies. (i) Classification as trade receivables Trade receivables are amounts due from customers for goods sold or services performed in the ordinary course of business. They are generally due for settlement within 30 days and therefore are all classified as current. Trade receivables are recognized initially at the amount of consideration that is unconditional unless they contain significant financing components, when they are recognized at fair value. The group holds the trade receivables with the objective to collect the contractual cash flows and therefore measures them subsequently at amortised cost using the effective interest method. Details about the group’s impairment policies and the calculation of the loss allowance are provided below. (ii) Accrued receivables These amounts primarily comprise receivables from the Australian Taxation Office in relation to the R&D tax incentive. (iii) Fair value of trade and other receivables Due to the short-term nature of the current receivables, their carrying amount is considered to be the same as their fair value. (iv) Impairment and risk exposure Information about the impairment of trade receivables and the group’s exposure to credit risk and foreign currency risk can be found in note 21.
Inventories	(m) Inventories Raw materials and stores, work in progress and finished goods Raw materials and stores, work in progress and finished goods are stated at the lower of cost and net realisable value. Cost comprises direct materials, direct labour and an appropriate proportion of variable and fixed overhead expenditure, the latter being allocated on the basis of normal operating capacity. Costs are assigned to individual items of inventory on the basis of weighted average costs. Costs of purchased inventory are determined after deducting rebates and discounts. Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.
Investments and other financial assets	(n) Investments and other financial assets (i) Classification The group classifies its financial assets in the following measurement categories: ● those to be measured subsequently at fair value (either through other comprehensive income or through profit or loss); and ● those to be measured at amortised cost. The classification depends on the group’s business model for managing the financial assets and the contractual terms of the cash flows. For assets measured at fair value, gains and losses will either be recorded in profit or loss and other comprehensive income. For investments in equity instruments that are not held for trading, this will depend on whether the group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through other comprehensive income (FVOCI). (ii) Recognition and derecognition Regular way purchases and sales of financial assets are recognized on trade-date, the date on which the group commits to purchase or sell the asset. Financial assets are derecognized when the rights to receive cash flows from the financial assets have expired or have been transferred and the group has transferred substantially all the risks and rewards of ownership. (iii) Measurement At initial recognition, the group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (FVPL), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVPL are expensed in profit or loss. (iv) Impairment The group assesses on a forward looking basis the expected credit losses associated with its debt instruments carried at amortised cost. The impairment methodology applied depends on whether there has been a significant increase in credit risk. For trade receivables, the group applies the simplified approach permitted by IFRS 9, which requires expected lifetime losses to be recognized from initial recognition of the receivables, see note 21(b) for further details. (v) Income recognition Interest income Interest income is recognized using the effective interest method. When a receivable is impaired, the group reduces the carrying amount to its recoverable amount, being the estimated future cash flow discounted at the original effective interest rate of the instrument, and continues unwinding the discount as interest income. Interest income on impaired loans is recognized using the original effective interest rate.
Property, plant and equipment	(o) Property, plant and equipment Property, plant and equipment is stated at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items. Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred. Depreciation is calculated using the straight-line method to allocate their cost or revalued amounts, net of their residual values, over their estimated useful lives or, in the case of leasehold improvements and certain leased plant and equipment, the shorter lease term as follows: ● Plant and equipment 2 - 5 years ● Furniture, fittings and equipment 3 - 15 years ● Right-of-use assets 3 years The assets’ residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period. An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying amount is greater than its estimated recoverable amount. Gains and losses on disposals are determined by comparing proceeds with carrying amount. These are included in profit or loss.
Intangible assets	(p) Intangible assets Research and development Expenditure on research activities, undertaken with the prospect of obtaining new scientific or technical knowledge and understanding, is recognized in the consolidated statement of profit or loss and other comprehensive income as an expense when it is incurred. Expenditure on development activities, being the application of research findings or other knowledge to a plan or design for the production of new or substantially improved products or services before the start of commercial production or use, is capitalised if it is probable that the product or service is technically and commercially feasible, will generate probable economic benefits, adequate resources are available to complete development and cost can be measured reliably. Other development expenditure is recognized in the consolidated statement of profit or loss and other comprehensive income as an expense as incurred.
Trade and other payables	(q) Trade and other payables These amounts represent liabilities for goods and services provided to the group prior to the end of financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting period. They are recognized initially at their fair value and subsequently measured at amortised cost using the effective interest method.
Employee benefits	(r) Employee benefits (i) Short-term obligations Liabilities for wages and salaries, including non-monetary benefits, annual leave and accumulating sick leave that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognized in respect of employees’ services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in the balance sheet. (ii) Other long-term employee benefit obligations In some countries, the group also has liabilities for long service leave and annual leave that are not expected to be settled wholly within 12 months after the end of the period in which the employees render the related service. These obligations are therefore measured as the present value of expected future payments to be made in respect of services provided by employees up to the end of the reporting period using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the end of the reporting period of high-quality corporate bonds with terms and currencies that match, as closely as possible, the estimated future cash outflows. Remeasurements as a result of experience adjustments and changes in actuarial assumptions are recognized in profit or loss. The obligations are presented as current liabilities in the balance sheet if the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period, regardless of when the actual settlement is expected to occur. (iii) Share-based payments Share-based compensation benefits are provided to employees via the ‘executive share and option plan’ (ESOP). Information relating to these schemes is set out in note 19. Employee options The fair value of options granted under the ESOP is recognized as a share-based payment expense with a corresponding increase in equity. The total amount to be expensed is determined by reference to the fair value of the options granted: - including any market performance conditions (e.g. the company’s share price); - excluding the impact of any service and non-market performance vesting conditions (e.g. profitability, sales growth targets and remaining an employee of the company over a specified time period); and - including the impact of any non-vesting conditions (e.g. the requirement for employees to save or holdings shares for a specific period of time). The total expense is recognized over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. At the end of each period, the entity revises its estimates of the number of options that are expected to vest based on the non-market vesting and service conditions. It recognizes the impact of the revision to original estimates, if any, in profit or loss, with a corresponding adjustment to equity.
Contributed equity	(s) Contributed equity Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.
Loss per share	(t) Loss per share (i) Basic loss per share Basic loss per share is calculated by dividing: ● the loss attributable to owners of the company, excluding any costs of servicing equity other than ordinary shares ● by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the year. (ii) Diluted loss per share Diluted loss per share adjusts the figures used in the determination of basic loss per share to take into account: ● the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares, and ● the weighted average number of additional ordinary shares that would have been outstanding assuming the conversion of all dilutive potential ordinary shares.
Rounding of amounts	(u) Rounding of amounts The company is of a kind referred to in ASIC Legislative Instrument 2016/191, relating to the ‘rounding off’ of amounts in the financial statements. Amounts in the financial statements have been rounded off in accordance with the instrument to the nearest dollar.
Goods and services tax (GST)	(v) Goods and services tax (GST) Revenues, expenses and assets are recognized net of the amount of associated GST, unless the GST incurred is not recoverable from the taxation authority. In this case it is recognized as part of the cost of acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the taxation authority is included with other receivables or payables in the consolidated balance sheet. Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the taxation authority, are presented as operating cash flows. Critical Accounting Estimates and Judgments Management evaluates estimates and judgments incorporated into the financial statements based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both internally and externally. Share-based payments The value attributed to share options and remunerations shares issued is an estimate calculated using an appropriate mathematical formula based on an option pricing model. The choice of models and the resultant option value require assumptions to be made in relation to the likelihood and timing of the conversion of the options to shares and the value of volatility of the price of the underlying shares. Fair value of options granted The assessed fair value of options at grant date was determined using the Black-Scholes option pricing model that takes into account the exercise price, term of the option, security price at grant date and expected price volatility of the underlying security, the expected dividend yield, the risk-free interest rate for the term of the security and certain probability assumptions. Impairment of inventories The provision for impairment of inventories assessment requires a degree of estimation and judgement. The level of the provision is assessed by taking into account the recent sales experience, the ageing of inventory, and in particular, the shelf life of inventories that affects obsolescence. Expected shelf-life is reassessed on a regular basis with reference to stability tests which are conducted by an expert engaged by the Company. A comprehensive stability study was completed in September 2019 and the reported findings support a shelf life of at least 130 months for the colostrum drug substance. There was a $328,833 (2020: Nil Nil Inventory split During the year ended 30 June 2021, management performed an assessment of its raw materials and utilisation within 12 months from reporting date. Management determined no raw materials relating to Colostrum will be consumed within 12 months from reporting date (2020: Nil Provision for employee benefits Provision for employee benefits represents amounts accrued for annual leave and long service leave. The current portion for this provision includes the total amount accrued for annual leave entitlements and the amounts accrued for long service leave entitlements that have vested due to employees having completed the required period of service. Refer to note 1(q) for policies on provisions. R&D tax incentive The Group’s research and development activities are eligible under an Australian Government tax incentive for eligible expenditure from July 1, 2011. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. For the year ended June 30, 2021 the Group has recorded other income of A$306,154 (2020: A$308,225) to recognise income over the year necessary to match the R&D tax incentive on a systematic basis with the costs that they are intended to compensate. Furthermore, the group subsequently received additional A$50,055 in current financial year as part of the R&D claim for financial year ended 30 June 2020. Fair value measurement hierarchy The preparation of the financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgments, estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgments, estimates, and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgments and estimates will seldom equal the related actual results. The judgments, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed within the relevant sections where applicable. The fair value of the convertible notes classified as Level 3 were determined by the use of valuation model. These include discounted cash flow analysis and the use of observable inputs that required significant adjustments based on unobservable inputs.

Revenue and other income (Table

Revenue and other income (Tables)	12 Months Ended
	Jun. 30, 2021
Disclosure of revenue [text block] [Abstract]
Schedule of revenue and other income	30 June 30 June 30 June A$ A$ A$ Revenue Revenue from Operating Activities Revenue from contracts with customers 145,776 2,518,566 2,387,426 Total Revenue from Operating Activities 145,776 2,518,566 2,387,426 Other Income Australian Federal R&D Tax Concession Refund 356,209 308,225 531,005 COVID-19 government assistance 161,600 154,904 - R&D grants 74,821 - - Other income 24,480 10,545 1,045 Total Other Income 617,110 473,674 532,050 Other Gains/(Losses) – Net Net foreign exchange gains/(losses) (582,528 ) 11,335 51,807 Net impairment losses (759,765 ) - (13,394 ) Total Other Gains/(Losses) – Net (1,342,293 ) 11,335 38,413

Expenses (Tables)

Expenses (Tables)	12 Months Ended
	Jun. 30, 2021
Disclosure of expenses by nature [text block] [Abstract]
Schedule of expenses	30 June 30 June 30 June General and administrative expenses Accounting and audit 547,055 389,798 496,983 Bad debts 5,472 26,983 50,429 Consulting 126,215 181,474 243,508 Depreciation 43,662 44,056 5,287 Employee benefits 1,775,809 1,531,037 1,599,023 Expected credit losses (30,055 ) (3,991 ) 34,046 Insurance 341,202 469,844 307,757 Investor relations 38,568 197,839 128,415 Legal 205,722 184,382 171,145 Listing and share registry 292,113 212,236 186,013 Occupancy - 51,973 105,606 Superannuation 41,964 48,877 55,176 Travel and entertainment 1,398 91,347 159,911 Other 589,554 278,135 151,007 3,978,679 3,703,990 3,694,306 Research and development expenses Consulting 1,006,086 262,720 430,996 Project research and development 360,968 915,965 613,532 1,367,054 1,178,685 1,044,528 Selling and marketing expenses Selling 25,858 340,046 277,478 Marketing 90,652 295,261 377,427 Distribution costs 171,174 236,244 209,739 287,684 871,551 864,644

Income Tax Benefit (Tables)

Income Tax Benefit (Tables)	12 Months Ended
	Jun. 30, 2021
Disclosure of income tax [text block] [Abstract]
Schedule of unused tax losses for which no deferred tax asset recognized	30 June 30 June Unused tax losses for which no deferred tax asset has been recognised 44,178,579 40,018,956 Potential tax benefit 26% (2020: 27.5%) 11,486,431 11,005,213
Schedule of income tax benefit	30 June 30 June Loss from continuing operations before income tax expense (8,384,465 ) (2,927,206 ) Tax at the Australian tax rate of 26% (2020: 27.5%) (2,179,961 ) (804,982 ) Tax effect of amounts which are not deductible (taxable) in calculating taxable income: R&D tax incentive (92,614 ) (84,762 ) Accounting expenditure subject to R&D tax incentive 212,907 194,855 Share-based payments 550,163 (146,826 ) Net impact of other amounts not deductible (taxable) 428,003 (18,678 ) Subtotal (1,081,502 ) (860,393 ) Tax losses and other timing differences for which no deferred tax asset is recognised 1,081,502 860,393 Income tax expense - -

Key Management Personnel Comp_2

Key Management Personnel Compensation (Tables)	12 Months Ended
	Jun. 30, 2021
Disclosure of information about key management personnel [text block] [Abstract]
Schedule of key management personnel compensation	30 June 30 June 30 June A$ A$ A$ Key Management Personnel Compensation Short-term employee benefits 450,002 867,054 952,406 Other short-term benefits, including consulting services by KMP and their related entities 1,603,747 - - Post-employment benefits 27,869 29,213 32,300 Long-term benefits 8,220 3,610 3,652 Share-based payment expenses to KMP and their related entities 2,116,012 73,088 1,296,400 Total Key Management Personnel Compensation 4,205,850 972,965 2,284,758

Loss per Share (Tables)

Loss per Share (Tables)	12 Months Ended
	Jun. 30, 2021
Disclosure of earnings per share [text block] [Abstract]
Schedule of basic and diluted loss per share	30 June 30 June 30 June A$ A$ A$ Basic/Diluted loss per share (in cents) 3.79 1.66 3.22 a) Net loss used in the calculation of basic and diluted loss per share 8,384,465 2,927,206 4,656,421 b) Weighted average number of ordinary shares outstanding during the period used in the calculation of basic and diluted loss per share 221,062,229 176,393,354 144,740,535

Cash (Tables)

Cash (Tables)	12 Months Ended
	Jun. 30, 2021
Disclosure Of Cash Explanatory [Abstract]
Schedule of balances under cash	30 June 30 June A$ A$ Cash at Bank and in hand: Cash at bank and in hand 25,047,281 3,250,468 Total Cash 25,047,281 3,250,468

Trade and Other Receivables (Ta

Trade and Other Receivables (Tables)	12 Months Ended
	Jun. 30, 2021
Disclosure of trade and other receivables [text block] [Abstract]
Schedule of trade and other receivables	30 June 30 June A$ A$ Current Trade receivables* 28,553 49,519 Loss allowance - (30,055 ) Accrued income** 306,154 308,225 Total Trade and Other Receivables 334,707 327,689 * All trade receivables are non-interest bearing. ** Primarily comprises of receivables from the Australian Tax Office in relation to R&D tax concession for the year.

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Jun. 30, 2021
Disclosure of inventories [text block] [Abstract]
Schedule of inventories	30 June 2021 30 June Current Non- Total Current Non- Total Raw materials and stores (Colostrum) - 1,266,587 1,266,587 - 1,722,349 1,722,349 Work in progress - - - 117,576 - 117,576 Finished goods (Travelan and Protectyn) 292,532 - 292,532 680,114 - 680,114 292,532 1,266,587 1,559,119 797,690 1,722,349 2,520,039

Controlled Entities (Tables)

Controlled Entities (Tables)	12 Months Ended
	Jun. 30, 2021
Controlled Entities [Abstract]
Schedule of subsidiaries	Percentage of Ownership Country of Incorporation 30 June 30 June Parent Entity: Immuron Limited Australia — — Subsidiaries of Immuron Limited: Immuron Inc. USA 100 % 100 % Anadis EPS Pty Ltd Australia 100 % 100 % IMC Canada Ltd. Canada 100 % 100 %

Trade and Other Payables (Table

Trade and Other Payables (Tables)	12 Months Ended
	Jun. 30, 2021
Disclosure of trade and other payables [text block] [Abstract]
Schedule of trade and other payables	30 June A$ 30 June A$ Current Trade payables 106,893 157,644 Accrued expenses 625,980 210,734 Other payables 25,621 16,019 Total 758,494 384,397

Provision for Sales Returns (Ta

Provision for Sales Returns (Tables)	12 Months Ended
	Jun. 30, 2021
Disclosure Of Provision For Sales Returns Explantory [Abstract]
Schedule of provision for sales returns	Sales return provision due to the ongoing COVID-19 pandemic 2021 Carrying amount at the start of the year - Sales return provision recognised 213,024 Amounts transferred from non-current - Carrying amount at the end of the year 213,024

Leases (Tables)

Leases (Tables)	12 Months Ended
	Jun. 30, 2021
Disclosure of leases [text block] [Abstract]
Schedule of amounts relating to leases in balance sheet	30 June 2021 30 June 2020 Right-of-use assets 1 Properties 19,471 58,095 19,471 58,095 Lease liabilities 2 Current 20,498 42,176 Non-current - 18,929 20,498 61,105 1. Included in the line item ‘property, plant and equipment’ in the consolidated balance sheet. 2. Included in the line items ‘other current liabilities’ and ‘other non-current liabilities’ in the consolidated balance sheet.
Schedule of profit or loss amounts relating to leases	2021 2020 Depreciation charge of right-of-use assets Properties 38,624 38,729 38,624 38,729 Interest expense (included in finance cost) 1,152 4,192 Expense relating to short-term leases (included in other expenses) - - Expense relating to leases of low-value assets that are not short-term leases (included in other expenses) - - Expense relating to variable lease payments not included in lease liabilities (included in other expenses) - - Cash paid for principal payments 40,607 41,390

Share Capital (Tables)

Share Capital (Tables)	12 Months Ended
	Jun. 30, 2021
Disclosure of classes of share capital [text block] [Abstract]
Schedule of share capital	2021 2020 2019 2021 2020 2019 Ordinary shares Fully paid 227,246,596 178,279,566 163,215,706 88,361,303 62,426,991 60,289,875 227,246,596 178,279,566 163,215,706 88,361,303 62,426,991 60,289,875
Schedule of ordinary shares	Details Number of shares Total Balance at 30 June 2018 142,778,206 58,237,314 Issue at $0.16 in lieu of payment for services (2018-11-22) 1 437,500 93,678 Issue at US$0.10 pursuant to ADS public offering (2019-05-30) 2 20,000,000 2,894,238 Reclassify exercised options from reserves to share capital — 100 Transaction costs arising on representative warrants issued 3 — (110,400 ) Less: Transaction costs arising on share issues — (825,055 ) Balance at 30 June 2019 163,215,706 60,289,875 Issue at US$0.10 pursuant to ADS public offering (2019-07-19) 13,565,200 1,926,186 Issue at A$0.16 in lieu of payment for services (2019-11-12) 1 437,500 100,978 Exercise of NASDAQ Warrants (2020-06-23) 86,240 72 Exercise of representative warrants (2020-06-15, 2020-06-22) 974,920 540,062 Transaction costs arising on representative warrants issued — (55,454 ) Less: Transaction costs arising on share issues — (374,728 ) Balance at 30 June 2020 178,279,566 62,426,991 Exercise of representative warrants (2020-07-02) 5,720 - Issue at US$0.47 pursuant to ADS public offering (2020-07-24) 42,666,720 28,165,836 Issue at $0.50 on exercise of ESOP unlisted options (2020-07-24) 100,000 50,000 Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-27) 3,008,000 1,051,626 Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-29) 40,000 13,959 Transfer from reserves on exercise of ESOP unlisted options (2020-07-24) - 15,700 Transfer from reserves on exercise of NASDAQ Warrants (2020-07-27, 2020-07-29) - 1,012 Issue at A$0.08 in lieu of cash for services rendered (2020-11-13) 2,737,500 219,000 Transfer from reserves on cashless exercise of ESOP unlisted options (2021-02-09) 409,090 197,010 Less: Transaction costs arising on share issues - (3,779,831 ) Balance at 30 June 2021 227,246,596 88,361,303 1. Mr Peter (resigned 24 September 2021) and Mr Stephen Anastasiou are directors and majority shareholders of Grandlodge Capital Pty Ltd (Grandlodge). As per an agreement which commenced on 1 June 2013 and expired on 30 June 2020, Immuron Limited contracted Grandlodge on normal commercial terms and conditions to provide warehousing, distribution and invoicing services for Immuron Limited’s products for A$70,000 per annum. These fees would be payable in new fully paid ordinary shares in Immuron Limited at a set price of A$0.16 per share, representing Immuron Limited’s shares price at the commencement of the agreement. The above amount is the fair value of the equity instrument. 2. On 30 May 2019, 500,000 American Depository Shares (ADS) were issued at US$4.00 each. Each ADS is equivalent to 40 ordinary shares, i.e. 20,000,000 at US$0.10 each (A$0.1447).

Other Reserves (Tables)

Other Reserves (Tables)	12 Months Ended
	Jun. 30, 2021
Disclosure of reserves within equity [text block] [Abstract]
Schedule of other reserves	Notes Share-based payments Foreign currency translation Total other reserves At 1 July 2018 3,139,625 (43,317 ) 3,096,308 Currency translation differences - 61,846 61,846 Other comprehensive income - 61,846 61,846 Transactions with owners in their capacity as owners Options and warrants issued/expensed 1,453,900 - 1,453,900 Options and warrants exercised (100 ) - (100 ) Options and warrants lapsed/expired (311,635 ) - (311,635 ) At 30 June 2019 4,281,790 18,529 4,300,319 Notes Share-based payments Foreign currency translation Total other reserves At 1 July 2019 4,281,790 18,529 4,300,319 Currency translation differences - 102,938 102,938 Other comprehensive income - 102,938 102,938 Transactions with owners in their capacity as owners Share-based payment expenses 16(iv) 73,088 - 73,088 Options and warrants issued/expensed (484,680 ) - (484,680 ) Options and warrants lapsed/expired (2,251,320 ) - (2,251,320 ) Re-valuation of options issued in prior period 16(iii) (607,000 ) - (607,000 ) At 30 June 2020 1,011,878 121,467 1,133,345 Notes Share-based payments Foreign currency translation Total other reserves At 1 July 2020 1,011,878 121,467 1,133,345 Currency translation differences - (14,953 ) (14,953 ) Other comprehensive income - (14,953 ) (14,953 ) Transactions with owners in their capacity as owners Transfer to share capital 16(iv) (73,088 ) - (73,088 ) Options and warrants issued/expensed 16(ii) 3,003,060 - 3,003,060 Options and warrants exercised 16(ii) (213,722 ) - (213,722 ) Options and warrants forfeited (368,000 ) - (368,000 ) At 30 June 2021 3,360,128 106,514 3,466,642
Schedule of movements in options and warrants	Details Notes Number of options Total Balance at 30 June 2018 72,569,180 3,139,625 Issue of ESOP unlisted options at $0.50 (2018-07-13) 1,300,000 204,100 Issue of ESOP unlisted options at $0.50 (2018-11-26) 2,000,000 164,400 Lapse of ESOP unlisted options at $0.50 (2018-10-01) (1,050,000 ) (98,385 ) Issue of ESOP unlisted options at $0.50 (2019-02-11) 5,000,000 975,000 Lapse of unlisted options at $0.57 (2019-02-24) (1,000,000 ) (185,601 ) Lapse of unlisted options at $1.892 (2019-02-28) (15,380 ) (1,173 ) Lapse of unlisted options at $0.30 (2019-05-28) (140,056 ) (13,390 ) Reclassify exercised options from reserves to share capital - (100 ) Reclassify lapsed options from reserves to accumulated losses - (13,086 ) Issue of representative warrants (2019-05-23) 1 800,000 110,400 Balance at 30 June 2019 79,463,744 4,281,790 Re-valuation of options issued in prior period (2019-11-06) 16(iii) - (607,000 ) Issue of representative warrants (2019-07-16) 542,600 55,454 Lapse of unexercised options at $0.50 (2019-11-27) (7,625,532 ) (2,086,920 ) Lapse of unexercised options at $0.55 (2019-11-30) (25,289,894 ) - Lapse of unexercised options at $0.50 (2020-06-30) (2,000,000 ) (164,400 ) Exercise of NASDAQ Warrants at US$10 per 40 options (2020-06-23) (218,800 ) (72 ) Exercise of representative warrants (2020-06-15, 2020-06-22) (2,065,000 ) (540,062 ) Balance at 30 June 2020 42,807,118 938,790 Exercise of representative warrants (2020-07-2) (9,640 ) - Exercise of ESOP unlisted options at $0.50 (2020-07-24) (100,000 ) (15,700 ) Exercise of NASDAQ Warrants at US$10 per 40 options (2020-07-27, 2020-07-29) (3,048,000 ) (1,012 ) Lapse of unexercised options (2020-09-25) (5,000,000 ) (368,000 ) Issue of representative warrants at US$23.44 per 40 options (2020-07-24) 2,560,000 1,032,960 Issue of ESOP unlisted options at $0.12 (2020-10-29) 9,000,000 1,970,100 Cashless exercise of ESOP unlisted options at $0.12 (2021-02-09) (900,000 ) (197,010 ) Reclassify share-based payments expenses from reserves to share capital 16(iv) - (73,088 ) Balance at 30 June 2021 45,309,478 3,360,128

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Jun. 30, 2021
Disclosure of entity's operating segments [text block] [Abstract]
Schedule of segment information for the reportable segments	Research and development Hyperimmune products Other Total 2021 A$ A$ A$ A$ Hyperimmune products revenue - 145,776 - 145,776 Cost of sales of goods - (51,071 ) - (51,071 ) Gross profit - 94,705 - 94,705 Other income 431,030 24,480 161,600 617,110 Other gains/(losses) – net - (759,765 ) (582,528 ) (1,342,293 ) General and administrative expenses - - (3,978,679 ) (3,978,679 ) Share-based payment expenses - - (2,116,013 ) (2,116,013 ) Research and development expenses (1,367,054 ) - - (1,367,054 ) Selling and marketing expenses - (287,684 ) - (287,684 ) Operating profit/(loss) (936,024 ) (928,264 ) (6,515,620 ) (8,379,908 ) Finance income - - 9,204 9,204 Finance costs - - (13,761 ) (13,761 ) Income tax expense - - - - Profit/(loss) for the year (936,024 ) (928,264 ) (6,520,177 ) (8,384,465 ) Assets Segment assets 306,154 1,587,672 25,159,280 27,053,106 Total assets 306,154 1,587,672 25,159,280 27,053,106 Liabilities Segment liabilities 243,565 284,657 629,827 1,158,049 Total liabilities 243,565 284,657 629,827 1,158,049 Research and development Hyperimmune products Other Total 2020 A$ A$ A$ A$ Hyperimmune products revenue - 2,518,566 - 2,518,566 Cost of sales of goods - (688,836 ) - (688,836 ) Gross profit - 1,829,730 - 1,829,730 Other income 308,225 10,545 154,904 473,674 Other gains/(losses) – net - - 11,335 11,335 General and administrative expenses - - (3,170,078 ) (3,170,078 ) Research and development expenses (1,178,685 ) - - (1,178,685 ) Selling and marketing expenses - (871,551 ) - (871,551 ) Operating profit/(loss) (870,460 ) 968,724 (3,003,839 ) (2,905,575 ) Finance income - - - - Finance costs - - (21,631 ) (21,631 ) Income tax expense - - - - Profit/(loss) for the year (870,460 ) 968,724 (3,025,470 ) (2,927,206 ) Assets Segment assets 308,225 2,539,503 3,354,435 6,202,163 Total assets 308,225 2,539,503 3,354,435 6,202,163 Liabilities Segment liabilities 101,092 30,377 426,781 558,250 Total liabilities 101,092 30,377 426,781 558,250 Research and development Hyperimmune products Other Total 2019 A$ A$ A$ A$ Hyperimmune products revenue - 2,387,426 - 2,387,426 Cost of sales of goods - (667,371 ) - (667,371 ) Gross profit - 1,720,055 - 1,720,055 Other income 531,005 1,045 - 532,050 Other gains/(losses) – net - (13,394 ) 51,807 38,413 General and administrative expenses - - (5,037,806 ) (5,037,806 ) Research and development expenses (1,044,528 ) - - (1,044,528 ) Selling and marketing expenses - (864,644 ) - (864,644 ) Operating profit/(loss) (513,523 ) 843,062 (4,985,999 ) (4,656,460 ) Finance income - - 39 39 Profit/(loss) for the year (513,523 ) 843,062 (4,985,960 ) (4,656,421 ) Assets Segment assets 531,828 2,705,330 5,324,489 8,561,647 Total assets 531,828 2,705,330 5,324,489 8,561,647 Liabilities Segment liabilities 221,520 191,836 797,155 1,210,511 Total liabilities 221,520 191,836 797,155 1,210,511
Schedule of information on geographical regions	Travelan Protectyn Australia United States Other Australia Other Total 2021 A$ A$ A$ A$ A$ A$ Hyperimmune products revenue 1 (10,308 ) 4,264 101,639 50,181 - 145,776 Revenue from external customers (10,308 ) 4,264 101,639 50,181 - 145,776 Travelan Protectyn Australia United States Other Australia Other Total 2020 A$ A$ A$ A$ A$ A$ Hyperimmune products revenue 1,240,393 926,325 301,915 49,933 - 2,518,566 Revenue from external customers 1,240,393 926,325 301,915 49,933 - 2,518,566 Travelan Protectyn Australia United States Other Australia Other Total 2019 A$ A$ A$ A$ A$ A$ Segment revenue 1,162,628 1,016,468 149,283 58,683 364 2,387,426 Revenue from external customers 1,162,628 1,016,468 149,283 58,683 364 2,387,426
Schedule of major customers	2021 A$ 2020 A$ 2019 A$ Customer A 41,040 - - Customer B 27,563 - - Customer C 25,319 - - Customer D 23,214 462,490 611,920 Customer E 22,886 - - Customer F - 442,916 228,661 Customer G - 438,065 659,637 Customer H - 327,559 266,111 Customer I - 227,952 249,522 140,022 1,898,982 2,015,851

Cash Flow Information (Tables)

Cash Flow Information (Tables)	12 Months Ended
	Jun. 30, 2021
Disclosure Of Cash Flow Information Explanatory [Abstract]
Schedule of reconciliation of cash flow from operations with loss after income tax	30 June 30 June 30 June Net Loss for the Year (8,384,465 ) (2,927,206 ) (4,656,421 ) Adjustments for Depreciation expense 43,662 44,056 5,287 Distribution costs - 70,000 70,000 Expected credit losses (30,055 ) (3,991 ) 34,046 Finance costs 13,761 21,631 — Finance income (9,204 ) - (39 ) Leave provision expense 53,610 19,717 4,580 Share-based payments (income)/expenses 2,116,013 (533,912 ) 1,343,500 Unrealized net foreign currency gains 592,243 (18,883 ) (62,015 ) Change in operating assets and liabilities: Add decrease in trade and other receivables 23,037 641,236 680,337 Add (increase) / decrease in inventories 960,920 (113,635 ) 263,365 Add (increase) / decrease in other operating assets (45,065 ) 16,096 92,510 Add (decrease) / increase in trade and other payables 586,796 (362,437 ) 426,271 (4,078,747 ) (3,147,328 ) (1,798,579 )

Share-based Payments (Tables)

Share-based Payments (Tables)	12 Months Ended
	Jun. 30, 2020
Share-based Payments (Tables) [Line Items]
Schedule of granted valuation of options	Expiry Exercise Share options Share options Grant date (A$ unless stated otherwise) 30 June 30 June 2012-06-29 2021-11-30 1.944 14,493 14,493 2012-06-29 2022-01-17 1.876 29,668 29,668 2017-06-13 (warrants) 2022-06-13 USD 0.25 24,493,200 27,541,200 2018-03-15 2023-03-15 0.468 7,897,647 7,897,647 2017-06-09 (warrants) 2022-06-08 USD 0.3125 198,240 198,240 2018-03-15 2023-03-15 0.585 526,510 526,510 2019-05-23 (warrants) 2024-05-23 USD 0.125 173,600 181,600 2019-07-16 (warrants) 2024-07-16 USD 0.125 116,120 117,760 2018-07-13 2021-07-01 0.500 1,200,000 1,300,000 2019-11-06 2024-02-10 0.500 - 5,000,000 2020-10-29 2024-04-14 0.12 8,100,000 - 2020-07-24 (warrants) 2025-07-21 USD 0.5859 2,560,000 - Total 45,309,478 42,807,118 Weighted average remaining contractual life of options outstanding at end of period 1.58 2.28
Schedule of total expenses arising from share-based payment transactions	2021 2020 1 2019 Options issued under ESOP 1,970,100 (607,000 ) 1,343,500 Share-based payments to directors 2 145,913 73,088 - 2,116,013 (533,912 ) 1,343,500
ESOP [Member]
Share-based Payments (Tables) [Line Items]
Schedule of movement in number of stock options outstanding and weighted average exercise price	2021 2020 2019 Average exercise price per share option (A$) Number of options Average exercise price per share option (A$) Number of options Average exercise price per share option (A$) Number of options As at 1 July 0.40 42,807,118 0.46 79,463,744 0.45 72,569,180 Granted during the year 0.28 11,560,000 0.18 542,600 0.47 9,100,000 Exercised during the year 0.23 (4,057,640 ) 0.18 (424,840 ) - - Forfeited/lapsed during the year 0.50 (5,000,000 ) 0.52 (36,774,386 ) 0.53 (2,205,436 ) As at 30 June 0.31 45,309,478 0.40 42,807,118 0.46 79,463,744 Vested and exercisable at 30 June 0.31 45,309,478 0.40 42,807,118 0.46 79,463,744
Schedule of granted valuation of options	Grant date Expiry date Exercise price No. of options Share price at grant date Expected volatility Dividend yield Risk- free interest rate Fair value 2020-07-24 2025-07-21 0.83 2,560,000 0.50 127.93 % 0.00 % 0.43 % 0.4035 2020-10-29 2024-04-14 0.12 9,000,000 0.25 142.70 % 0.00 % 0.13 % 0.2189 11,560,000 Grant date Expiry date Exercise No. of Share price at grant date Expected Dividend Risk- free Fair value 2019-11-06 2024-02-10 0.50 5,000,000 0.15 98 0.00 % 0.88 % 0.0736 5,000,000 Grant date Expiry date Exercise No. of Share price at grant date Expected Dividend Risk- free Fair value 2018-07-13 2021-07-01 0.50 1,300,000 0.32 92.00 % 0.00 % 2.09 % 0.1570 2018-11-26 2020-06-30 0.50 2,000,000 0.34 92.00 % 0.00 % 2.02 % 0.0822 2019-02-11 2024-02-11 0.50 5,000,000 0.29 100.00 % 0.00 % 1.69 % 0.1950 8,300,000

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Jun. 30, 2021
Disclosure of related party [text block] [Abstract]
Schedule of information about other related party transactions	2021 2020 2019 Amounts settled in cash or shares for goods and services Purchases of various goods and services from entities controlled by key management personnel (i) 110,607 142,347 147,636 2020 2020 2019 Amounts settled in cash or shares during the period Rental of an office suite from Wattle Laboratories Pty Ltd 40,607 41,369 53,958 Services rendered by Grandlodge Capital Pty Ltd 70,000 100,978 93,678 110,607 142,347 147,636
Schedule of outstanding balances transactions between related parties	2021 A$ 2020 A$ 2019 A$ Current payables (purchases of goods and services) Entities controlled by key management personnel 70,000 - -

Financial Risk Management Obj_2

Financial Risk Management Objectives and Policies (Tables)	12 Months Ended
	Jun. 30, 2021
Disclosure of financial risk management [text block] [Abstract]
Schedule of foreign currency risk	2021 2020 USD CAD USD CAD ILS Cash and cash equivalents 2,742,688 108,688 2,954,589 107,605 - Trade receivables 23,801 - 45,591 - - Trade payables 18,556 43,466 29,946 1,923 41,771 Total exposure 2,785,045 152,154 3,030,126 109,528 41,771
Schedule of exchange rates	Impact on loss for Impact on other components 2021 2020 2021 2020 USD/AUD exchange rate – change by 4.9% (2020: 3.3%) 136,467 99,994 5,219 4,035
Schedule of trade receivables	Days past due Current 1-30 31-60 61-90 91-120 121+ Total 30 June 2021 A$ A$ A$ A$ A$ A$ A$ Expected credit loss rate 0.00 % 0.00 % 13.07 % 21.88 % 34.09 % 53.58 % Gross carrying amount 23,801 4,752 - - - - 28,553 Loss allowance - - - - - - - Days past due 30 June 2020 Current 1-30 31-60 61-90 91-120 121+ Total Expected credit loss rate 0.60 % 8.06 % 0.00 % 23.35 % 38.30 % 100.00 % Gross carrying amount 2,820 1,055 - 14,476 7,447 23,721 49,519 Loss allowance 17 85 - 3,380 2,852 23,721 30,055
Schedule of contractual undiscounted cash flows	Contractual maturities of financial liabilities Less than 6 months 6 - 12 months Between 1 and 2 years Between 2 and 5 years Over 5 years Total contractual cash flows Carrying amount (assets)/ liabilities At 30 June 2021 A$ A$ A$ A$ A$ A$ A$ Trade and other payables 132,514 - - - - 132,514 132,514 Lease liabilities 20,498 - - - - 20,498 20,498 Total 153,012 - - - - 153,012 153,012 At 30 June 2020 Trade and other payables 173,663 - - - - 173,663 173,663 Lease liabilities 20,890 21,286 21,286 - - 63,462 63,462 Total 194,553 21,286 21,286 - - 237,125 237,125

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Jun. 30, 2021AUD ($)	Jun. 30, 2020AUD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2017USD ($)
Summary of Significant Accounting Policies (Details) [Line Items]
Representative warrants (in Dollars)					$ 110,400	$ 489,586
Share capital (in Dollars)					$ 800,000	$ 1,220,000
Assistance packages	$ 154,904
Finished goods	328,833
Raw materials (in Dollars)			$ 430,932
Raw materials
Raw materials non-current	1,266,587	1,722,349
Other income R&D tax concession refund	$ 306,154	308,225
Additional R&D fund		$ 50,055
Plant and Equipment [Member] | Bottom of range [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Estimated useful lives	2 years
Plant and Equipment [Member] | Top of range [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Estimated useful lives	5 years
Furniture, fittings and equipment [Member] | Bottom of range [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Estimated useful lives	3 years
Furniture, fittings and equipment [Member] | Top of range [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Estimated useful lives	15 years
Right-of-use assets [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Estimated useful lives	3 years

Revenue and other income (Detai

Revenue and other income (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure of revenue [text block] [Abstract]
Other income	$ 306,154	$ 308,225
Additional other income		50,055
Government assistance packages	161,600	154,904
R&D grant	$ 74,821

Revenue and other income (Det_2

Revenue and other income (Details) - Schedule of revenue and other income - AUD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Revenue from Operating Activities
Revenue from contracts with customers	$ 145,776	$ 2,518,566	$ 2,387,426
Total Revenue from Operating Activities	145,776	2,518,566	2,387,426
Other Income
Australian Federal R&D Tax Concession Refund	356,209	308,225	531,005
COVID-19 government assistance	161,600	154,904
R&D grants	74,821
Other income	24,480	10,545	1,045
Total Other Income	617,110	473,674	532,050
Other Gains/(Losses) – Net
Net foreign exchange gains/(losses)	(582,528)	11,335	51,807
Net impairment losses	(759,765)		(13,394)
Total Other Gains/(Losses) – Net	$ (1,342,293)	$ 11,335	$ 38,413

Expenses (Details) - Schedule o

Expenses (Details) - Schedule of expenses - AUD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
General and administrative expenses
Accounting and audit	$ 547,055	$ 389,798	$ 496,983
Bad debts	5,472	26,983	50,429
Consulting	126,215	181,474	243,508
Depreciation	43,662	44,056	5,287
Employee benefits	1,775,809	1,531,037	1,599,023
Expected credit losses	(30,055)	(3,991)	34,046
Insurance	341,202	469,844	307,757
Investor relations	38,568	197,839	128,415
Legal	205,722	184,382	171,145
Listing and share registry	292,113	212,236	186,013
Occupancy		51,973	105,606
Superannuation	41,964	48,877	55,176
Travel and entertainment	1,398	91,347	159,911
Other	589,554	278,135	151,007
Total general and administrative expenses	3,978,679	3,703,990	3,694,306
Research and development expenses
Consulting	1,006,086	262,720	430,996
Project research and development	360,968	915,965	613,532
Total research and development expenses	1,367,054	1,178,685	1,044,528
Selling and marketing expenses
Selling	25,858	340,046	277,478
Marketing	90,652	295,261	377,427
Distribution costs	171,174	236,244	209,739
Total selling and marketing expenses	$ 287,684	$ 871,551	$ 864,644

Income Tax Benefit (Details) -

Income Tax Benefit (Details) - Schedule of unused tax losses for which no deferred tax asset recognized - AUD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Schedule of unused tax losses for which no deferred tax asset recognized [Abstract]
Unused tax losses for which no deferred tax asset has been recognised	$ 44,178,579	$ 40,018,956
Potential tax benefit @ 26% (2020: 27.5%)	$ 11,486,431	$ 11,005,213

Income Tax Benefit (Details) _2

Income Tax Benefit (Details) - Schedule of income tax benefit - AUD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Schedule of income tax benefit [Abstract]
Loss from continuing operations before income tax expense	$ (8,384,465)	$ (2,927,206)	$ (4,656,421)
Tax at the Australian tax rate of 26% (2020: 27.5%)	(2,179,961)	(804,982)
R&D tax incentive	(92,614)	(84,762)
Accounting expenditure subject to R&D tax incentive	212,907	194,855
Share-based payments	550,163	(146,826)
Net impact of other amounts not deductible (taxable)	428,003	(18,678)
Subtotal	(1,081,502)	(860,393)
Tax losses and other timing differences for which no deferred tax asset is recognised	1,081,502	860,393
Income tax expense

Key Management Personnel Comp_3

Key Management Personnel Compensation (Details) - Schedule of key management personnel compensation - AUD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Key Management Personnel Compensation
Short-term employee benefits	$ 450,002	$ 867,054	$ 952,406
Other short-term benefits, including consulting services by KMP and their related entities	1,603,747
Post-employment benefits	27,869	29,213	32,300
Long-term benefits	8,220	3,610	3,652
Share-based payment expenses to KMP and their related entities	2,116,012	73,088	1,296,400
Total Key Management Personnel Compensation	$ 4,205,850	$ 972,965	$ 2,284,758

Loss per Share (Details) - Sche

Loss per Share (Details) - Schedule of basic and diluted loss per share - AUD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Schedule of basic and diluted loss per share [Abstract]
Basic/Diluted loss per share (in cents)	$ 3.79	$ 1.66	$ 3.22
a) Net loss used in the calculation of basic and diluted loss per share	$ 8,384,465	$ 2,927,206	$ 4,656,421
b) Weighted average number of ordinary shares outstanding during the period used in the calculation of basic and diluted loss per share	221,062,229	176,393,354	144,740,535

Cash (Details) - Schedule of ba

Cash (Details) - Schedule of balances under cash - AUD ($)	Jun. 30, 2021	Jun. 30, 2020
Cash at Bank and in hand:
Cash at bank and in hand	$ 25,047,281	$ 3,250,468
Total Cash	$ 25,047,281	$ 3,250,468

Trade and Other Receivables (De

Trade and Other Receivables (Details) - Schedule of trade and other receivables - AUD ($)		Jun. 30, 2021	Jun. 30, 2020
Current
Trade receivables	[1]	$ 28,553	$ 49,519
Loss allowance			(30,055)
Accrued income	[2]	306,154	308,225
Total Trade and Other Receivables		$ 334,707	$ 327,689
[1]	All trade receivables are non-interest bearing.
[2]	Primarily comprises of receivables from the Australian Tax Office in relation to R&D tax concession for the year.

Inventories (Details) - Schedul

Inventories (Details) - Schedule of inventories - AUD ($)	Jun. 30, 2021	Jun. 30, 2020
Inventories (Details) - Schedule of inventories [Line Items]
Inventories Current	$ 292,532	$ 797,690
Inventories Non- current	1,266,587	1,722,349
Net	1,559,119	2,520,039
Raw materials and stores (Colostrum) [Member]
Inventories (Details) - Schedule of inventories [Line Items]
Inventories Current
Inventories Non- current	1,266,587	1,722,349
Net	1,266,587	1,722,349
Work in progress [Member]
Inventories (Details) - Schedule of inventories [Line Items]
Inventories Current		117,576
Inventories Non- current
Net		117,576
Finished goods (Travelan and Protectyn) [Member]
Inventories (Details) - Schedule of inventories [Line Items]
Inventories Current	292,532	680,114
Inventories Non- current
Net	$ 292,532	$ 680,114

Controlled Entities (Details) -

Controlled Entities (Details) - Schedule of subsidiaries	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Immuron Limited [Member]
Parent Entity:
Country of Incorporation	Australia
Percentage of Ownership
Immuron Inc [Member]
Parent Entity:
Country of Incorporation	USA
Percentage of Ownership	100.00%	100.00%
Anadis EPS Pty Ltd [Member]
Parent Entity:
Country of Incorporation	Australia
Percentage of Ownership	100.00%	100.00%
IMC Canada Ltd [Member]
Parent Entity:
Country of Incorporation	Canada
Percentage of Ownership	100.00%	100.00%

Trade and Other Payables (Detai

Trade and Other Payables (Details) - Schedule of trade and other payables - AUD ($)	Jun. 30, 2021	Jun. 30, 2020
Current
Trade payables	$ 106,893	$ 157,644
Accrued expenses	625,980	210,734
Other payables	25,621	16,019
Total	$ 758,494	$ 384,397

Provision for Sales Returns (De

Provision for Sales Returns (Details) - Schedule of provision for sales returns	12 Months Ended
	Jun. 30, 2021AUD ($)
Schedule of provision for sales returns [Abstract]
Carrying amount at the start of the year
Sales return provision recognised	213,024
Amounts transferred from non-current
Carrying amount at the end of the year	$ 213,024

Contingent liabilities and Co_2

Contingent liabilities and Commitments (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Contingent Liabilities [Abstract]
Contingent liabilities	$ 0

Leases (Details)

Leases (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure of leases [text block] [Abstract]
Finance cash outflow for leases	$ 1,152	$ 4,192
Lease, description	In January 2019, the group entered into a three-year commercial lease in Blackburn North. The lease is for the use of warehousing and office facilities. This lease includes an extension option for a further 3 years by written request to the landlord before 31 December 2021.

Leases (Details) - Schedule of

Leases (Details) - Schedule of amounts relating to leases in balance sheet - AUD ($)		Jun. 30, 2021	Jun. 30, 2020
Leases (Details) - Schedule of amounts relating to leases in balance sheet [Line Items]
Right-of-use assets	[1]	$ 19,471	$ 58,095
Current	[2]	20,498	42,176
Non-current	[2]		18,929
Total lease liabilities	[2]	20,498	61,105
Properties [Member]
Leases (Details) - Schedule of amounts relating to leases in balance sheet [Line Items]
Right-of-use assets	[1]	$ 19,471	$ 58,095
[1]	Included in the line item ‘property, plant and equipment’ in the consolidated balance sheet.
[2]	Included in the line items ‘other current liabilities’ and ‘other non-current liabilities’ in the consolidated balance sheet.

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of profit or loss amounts relating to leases - AUD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Depreciation charge of right-of-use assets
Depreciation charge of right-of-use assets	$ 38,624	$ 38,729
Interest expense (included in finance cost)	1,152	4,192
Expense relating to short-term leases (included in other expenses)
Expense relating to leases of low-value assets that are not short-term leases (included in other expenses)
Expense relating to variable lease payments not included in lease liabilities (included in other expenses)
Cash paid for principal payments	40,607	41,390
Properties [Member]
Depreciation charge of right-of-use assets
Depreciation charge of right-of-use assets	$ 38,624	$ 38,729

Share Capital (Details)

Share Capital (Details) - AUD ($)	1 Months Ended	12 Months Ended
	May 30, 2019	Jun. 30, 2021
Disclosure of classes of share capital [text block] [Abstract]
Payment for services		$ 70,000
New fully paid ordinary per share		$ 0.16
Issuance of ordinary shares, description	On 30 May 2019, 500,000 American Depository Shares (ADS) were issued at US$4.00 each. Each ADS is equivalent to 40 ordinary shares, i.e. 20,000,000 at US$0.10 each (A$0.1447).

Share Capital (Details) - Sched

Share Capital (Details) - Schedule of share capital - AUD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Schedule of share capital [Abstract]
Ordinary shares	227,246,596	178,279,566	163,215,706
Ordinary shares, value	$ 88,361,303	$ 62,426,991	$ 60,289,875
Ordinary shares, Fully paid, shares	227,246,596	178,279,566	163,215,706
Ordinary shares, Fully paid, value	$ 88,361,303	$ 62,426,991	$ 60,289,875

Share Capital (Details) - Sch_2

Share Capital (Details) - Schedule of ordinary shares - USD ($)		12 Months Ended
		Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Schedule of ordinary shares [Abstract]
Balance, shares		178,279,566	163,215,706	142,778,206
Balance		$ 62,426,991	$ 60,289,875	$ 58,237,314
Issue at US$0.10 pursuant to ADS public offering (2019-07-19)			13,565,200
Issue at US$0.10 pursuant to ADS public offering (2019-07-19)			$ 1,926,186
Issue at A$0.16 in lieu of payment for services (2019-11-12)1	[1]		437,500
Issue at A$0.16 in lieu of payment for services (2019-11-12)1	[1]		$ 100,978
Exercise of NASDAQ Warrants (2020-06-23)			86,240
Exercise of NASDAQ Warrants (2020-06-23)			$ 72
Exercise of representative warrants (2020-06-15, 2020-06-22)			974,920
Exercise of representative warrants (2020-06-15, 2020-06-22)			$ 540,062
Exercise of representative warrants (2020-07-02)		5,720
Exercise of representative warrants (2020-07-02)
Issue at US$0.47 pursuant to ADS public offering (2020-07-24)		42,666,720
Issue at US$0.47 pursuant to ADS public offering (2020-07-24)		$ 28,165,836
Issue at $0.50 on exercise of ESOP unlisted options (2020-07-24)		100,000
Issue at $0.50 on exercise of ESOP unlisted options (2020-07-24)		$ 50,000
Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-27)		3,008,000
Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-27)		$ 1,051,626
Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-29)		40,000
Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-29)		$ 13,959
Transfer from reserves on exercise of ESOP unlisted options (2020-07-24)
Transfer from reserves on exercise of ESOP unlisted options (2020-07-24)		$ 15,700
Transfer from reserves on exercise of NASDAQ Warrants (2020-07-27, 2020-07-29)
Transfer from reserves on exercise of NASDAQ Warrants (2020-07-27, 2020-07-29)		$ 1,012
Issue at A$0.08 in lieu of cash for services rendered (2020-11-13)		2,737,500
Issue at A$0.08 in lieu of cash for services rendered (2020-11-13)		$ 219,000
Transfer from reserves on cashless exercise of ESOP unlisted options (2021-02-09)		409,090
Transfer from reserves on cashless exercise of ESOP unlisted options (2021-02-09)		$ 197,010
Issue at $0.16 in lieu of payment for services (2018-11-22)1	[1]			437,500
Issue at $0.16 in lieu of payment for services (2018-11-22)1	[1]			$ 93,678
Issue at US$0.10 pursuant to ADS public offering (2019-05-30)2	[2]			20,000,000
Issue at US$0.10 pursuant to ADS public offering (2019-05-30)2	[2]			$ 2,894,238
Reclassify exercised options from reserves to share capital
Reclassify exercised options from reserves to share capital				$ 100
Transaction costs arising on representative warrants issued
Transaction costs arising on representative warrants issued			$ (55,454)	$ (110,400)
Less: Transaction costs arising on share issues
Less: Transaction costs arising on share issues		$ (3,779,831)	$ (374,728)	$ (825,055)
Balance, shares		227,246,596	178,279,566	163,215,706
Balance		$ 88,361,303	$ 62,426,991	$ 60,289,875
[1]	Mr Peter (resigned 24 September 2021) and Mr Stephen Anastasiou are directors and majority shareholders of Grandlodge Capital Pty Ltd (Grandlodge). As per an agreement which commenced on 1 June 2013 and expired on 30 June 2020, Immuron Limited contracted Grandlodge on normal commercial terms and conditions to provide warehousing, distribution and invoicing services for Immuron Limited’s products for A$70,000 per annum. These fees would be payable in new fully paid ordinary shares in Immuron Limited at a set price of A$0.16 per share, representing Immuron Limited’s shares price at the commencement of the agreement. The above amount is the fair value of the equity instrument.
[2]	On 30 May 2019, 500,000 American Depository Shares (ADS) were issued at US$4.00 each. Each ADS is equivalent to 40 ordinary shares, i.e. 20,000,000 at US$0.10 each (A$0.1447).

Other Reserves (Details)

Other Reserves (Details)	Feb. 11, 2019$ / sharesshares	Jul. 13, 2018$ / sharesshares	Oct. 29, 2020USD ($)	Jun. 30, 2019USD ($)	Nov. 26, 2018$ / sharesshares	Jun. 30, 2021USD ($)	Jun. 30, 2021AUD ($)
Other Reserves (Details) [Line Items]
ESOP options issued			$ 9,000,000
Revaluation financials amount				$ 607,000		$ 607,000
Value of shares owed (in Dollars)							$ 73,088
Dr. Jerry Kanellos [Member]
Other Reserves (Details) [Line Items]
Maturity date, description		Jerry Kanellos, Chief Operating Officer of Immuron Limited, 1,000,000 unlisted options exercisable at $0.50 on or before 1 July 2021.
Number of shares unlisted option (in Shares) | shares		1,000,000
Unlisted option exercisable per shares (in Dollars per share) | $ / shares		$ 0.5
Mr. Richard J. Berman [Member]
Other Reserves (Details) [Line Items]
Maturity date, description					On 26 November 2018, the Company issued Mr. Richard J. Berman, a Non-Executive Director of Immuron Limited, 2,000,000 unlisted options exercisable at $0.50 on or before June 30, 2021.
Number of shares unlisted option (in Shares) | shares					2,000,000
Unlisted option exercisable per shares (in Dollars per share) | $ / shares					$ 0.5
Dr. Gary S. Jacob [Member]
Other Reserves (Details) [Line Items]
Number of shares unlisted option (in Shares) | shares	5,000,000
Unlisted option exercisable per shares (in Dollars per share) | $ / shares	$ 0.5
Options granted				$ 975,000
Grant date, description				In line with IFRS 2, these were re-measured at grant date 6 November 2019 after being approved by shareholders with a value of $368,000, being a revaluation of $607,000 in the 30 June 2020 financials.
Revaluation of options value				$ 368,000

Other Reserves (Details) - Sche

Other Reserves (Details) - Schedule of other reserves - AUD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Other Reserves (Details) - Schedule of other reserves [Line Items]
Balance	$ 1,133,345	$ 4,300,319	$ 3,096,308
Other comprehensive income	(14,953)		61,846
Transactions with owners in their capacity as owners
Transfer to share capital	(73,088)
Options and warrants issued/expensed	3,003,060		1,453,900
Options and warrants exercised	(213,722)		(100)
Options and warrants forfeited	(368,000)
Options and warrants lapsed/expired			(311,635)
Re-valuation of options issued in prior period		(607,000)
Balance	3,466,642	1,133,345	4,300,319
Currency translation differences	(14,953)		61,846
Share-based payments [Member]
Other Reserves (Details) - Schedule of other reserves [Line Items]
Balance	1,011,878	4,281,790	3,139,625
Other comprehensive income
Transactions with owners in their capacity as owners
Transfer to share capital	(73,088)
Share-based payment expenses		73,088
Options and warrants issued/expensed	3,003,060	(484,680)	1,453,900
Options and warrants exercised	(213,722)		(100)
Options and warrants forfeited	(368,000)
Options and warrants lapsed/expired		(2,251,320)	(311,635)
Re-valuation of options issued in prior period		(607,000)
Balance	3,360,128	1,011,878	4,281,790
Currency translation differences
Foreign currency translation [Member]
Other Reserves (Details) - Schedule of other reserves [Line Items]
Balance	121,467	18,529	(43,317)
Other comprehensive income	(14,953)	102,938	61,846
Transactions with owners in their capacity as owners
Transfer to share capital
Share-based payment expenses
Options and warrants issued/expensed
Options and warrants exercised
Options and warrants forfeited
Options and warrants lapsed/expired
Re-valuation of options issued in prior period
Balance	106,514	121,467	18,529
Currency translation differences	$ (14,953)	$ 102,938	$ 61,846

Other Reserves (Details) - Sc_2

Other Reserves (Details) - Schedule of movements in options and warrants - AUD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Schedule of movements in options and warrants [Abstract]
Balance	42,807,118	79,463,744	72,569,180
Balance (in Dollars)	$ 938,790	$ 4,281,790	$ 3,139,625
Re-valuation of options issued in prior period (2019-11-06)
Re-valuation of options issued in prior period (2019-11-06) (in Dollars)		$ (607,000)
Issue of representative warrants (2019-07-16)		542,600
Issue of representative warrants (2019-07-16) (in Dollars)		$ 55,454
Lapse of unexercised options at $0.50 (2019-11-27)		(7,625,532)
Lapse of unexercised options at $0.50 (2019-11-27) (in Dollars)		$ (2,086,920)
Lapse of unexercised options at $0.55 (2019-11-30)		(25,289,894)
Lapse of unexercised options at $0.55 (2019-11-30) (in Dollars)
Lapse of unexercised options at $0.50 (2020-06-30)		(2,000,000)
Lapse of unexercised options at $0.50 (2020-06-30) (in Dollars)		$ (164,400)
Exercise of NASDAQ Warrants at US$10 per 40 options (2020-06-23)		(218,800)
Exercise of NASDAQ Warrants at US$10 per 40 options (2020-06-23) (in Dollars)		$ (72)
Exercise of representative warrants (2020-06-15, 2020-06-22)		(2,065,000)
Exercise of representative warrants (2020-06-15, 2020-06-22) (in Dollars)		$ (540,062)
Exercise of representative warrants (2020-07-2)	(9,640)
Exercise of representative warrants (2020-07-2) (in Dollars)
Exercise of ESOP unlisted options at $0.50 (2020-07-24)	(100,000)
Exercise of ESOP unlisted options at $0.50 (2020-07-24) (in Dollars)	$ (15,700)
Exercise of NASDAQ Warrants at US$10 per 40 options (2020-07-27, 2020-07-29)	(3,048,000)
Exercise of NASDAQ Warrants at US$10 per 40 options (2020-07-27, 2020-07-29) (in Dollars)	$ (1,012)
Lapse of unexercised options (2020-09-25)	(5,000,000)
Lapse of unexercised options (2020-09-25) (in Dollars)	$ (368,000)
Issue of representative warrants at US$23.44 per 40 options (2020-07-24)	2,560,000
Issue of representative warrants at US$23.44 per 40 options (2020-07-24) (in Dollars)	$ 1,032,960
Issue of ESOP unlisted options at $0.12 (2020-10-29)	9,000,000
Issue of ESOP unlisted options at $0.12 (2020-10-29) (in Dollars)	$ 1,970,100
Cashless exercise of ESOP unlisted options at $0.12 (2021-02-09)	(900,000)
Cashless exercise of ESOP unlisted options at $0.12 (2021-02-09) (in Dollars)	$ (197,010)
Reclassify share-based payments expenses from reserves to share capital
Reclassify share-based payments expenses from reserves to share capital (in Dollars)	$ (73,088)
Issue of ESOP unlisted options at $0.50 (2018-07-13)			1,300,000
Issue of ESOP unlisted options at $0.50 (2018-07-13) (in Dollars)			$ 204,100
Issue of ESOP unlisted options at $0.50 (2018-11-26)			2,000,000
Issue of ESOP unlisted options at $0.50 (2018-11-26) (in Dollars)			$ 164,400
Lapse of ESOP unlisted options at $0.50 (2018-10-01)			(1,050,000)
Lapse of ESOP unlisted options at $0.50 (2018-10-01) (in Dollars)			$ (98,385)
Issue of ESOP unlisted options at $0.50 (2019-02-11)			5,000,000
Issue of ESOP unlisted options at $0.50 (2019-02-11) (in Dollars)			$ 975,000
Lapse of unlisted options at $0.57 (2019-02-24)			(1,000,000)
Lapse of unlisted options at $0.57 (2019-02-24) (in Dollars)			$ (185,601)
Lapse of unlisted options at $1.892 (2019-02-28)			(15,380)
Lapse of unlisted options at $1.892 (2019-02-28) (in Dollars)			$ (1,173)
Lapse of unlisted options at $0.30 (2019-05-28)			(140,056)
Lapse of unlisted options at $0.30 (2019-05-28) (in Dollars)			$ (13,390)
Reclassify exercised options from reserves to share capital
Reclassify exercised options from reserves to share capital (in Dollars)			$ (100)
Reclassify lapsed options from reserves to accumulated losses
Reclassify lapsed options from reserves to accumulated losses (in Dollars)			$ (13,086)
Issue of representative warrants (2019-05-23)			800,000
Issue of representative warrants (2019-05-23) (in Dollars)			$ 110,400
Balance	45,309,478	42,807,118	79,463,744
Balance (in Dollars)	$ 3,360,128	$ 938,790	$ 4,281,790

Segment Reporting (Details)

Segment Reporting (Details)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Disclosure of entity's operating segments [text block] [Abstract]
Number of segment	2
Percentage of total revenue for major customer	10.00%	10.00%	10.00%

Segment Reporting (Details) - S

Segment Reporting (Details) - Schedule of segment information for the reportable segments - AUD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Segment Reporting (Details) - Schedule of segment information for the reportable segments [Line Items]
Hyperimmune products revenue	$ 145,776	$ 2,518,566	$ 2,387,426
Cost of sales of goods	(51,071)	(688,836)	(667,371)
Gross profit	94,705	1,829,730	1,720,055
Other income	617,110	473,674	532,050
Other gains/(losses) – net	(1,342,293)	11,335	38,413
General and administrative expenses	(3,978,679)	(3,170,078)	(5,037,806)
Share-based payment expenses	(2,116,013)
Research and development expenses	(1,367,054)	(1,178,685)	(1,044,528)
Selling and marketing expenses	(287,684)	(871,551)	(864,644)
Operating profit/(loss)	(8,379,908)	(2,905,575)	(4,656,460)
Finance income	9,204		39
Finance costs	(13,761)	(21,631)
Income tax expense
Profit/(loss) for the year	(8,384,465)	(2,927,206)	(4,656,421)
Assets
Segment assets	27,053,106	6,202,163	8,561,647
Total assets	27,053,106	6,202,163	8,561,647
Liabilities
Segment liabilities	1,158,049	558,250	1,210,511
Total liabilities	1,158,049	558,250	1,210,511
Research and Development [Member]
Segment Reporting (Details) - Schedule of segment information for the reportable segments [Line Items]
Hyperimmune products revenue
Cost of sales of goods
Gross profit
Other income	431,030	308,225	531,005
Other gains/(losses) – net
General and administrative expenses
Share-based payment expenses
Research and development expenses	(1,367,054)	(1,178,685)	(1,044,528)
Selling and marketing expenses
Operating profit/(loss)	(936,024)	(870,460)	(513,523)
Finance income
Finance costs
Income tax expense
Profit/(loss) for the year	(936,024)	(870,460)	(513,523)
Assets
Segment assets	306,154	308,225	531,828
Total assets	306,154	308,225	531,828
Liabilities
Segment liabilities	243,565	101,092	221,520
Total liabilities	243,565	101,092	221,520
HyperImmune Products [Member]
Segment Reporting (Details) - Schedule of segment information for the reportable segments [Line Items]
Hyperimmune products revenue	145,776	2,518,566	2,387,426
Cost of sales of goods	(51,071)	(688,836)	(667,371)
Gross profit	94,705	1,829,730	1,720,055
Other income	24,480	10,545	1,045
Other gains/(losses) – net	(759,765)		(13,394)
General and administrative expenses
Share-based payment expenses
Research and development expenses
Selling and marketing expenses	(287,684)	(871,551)	(864,644)
Operating profit/(loss)	(928,264)	968,724	843,062
Finance income
Finance costs
Income tax expense
Profit/(loss) for the year	(928,264)	968,724	843,062
Assets
Segment assets	1,587,672	2,539,503	2,705,330
Total assets	1,587,672	2,539,503	2,705,330
Liabilities
Segment liabilities	284,657	30,377	191,836
Total liabilities	284,657	30,377	191,836
Other [Member]
Segment Reporting (Details) - Schedule of segment information for the reportable segments [Line Items]
Hyperimmune products revenue
Cost of sales of goods
Gross profit
Other income	161,600	154,904
Other gains/(losses) – net	(582,528)	11,335	51,807
General and administrative expenses	(3,978,679)	(3,170,078)	(5,037,806)
Share-based payment expenses	(2,116,013)
Research and development expenses
Selling and marketing expenses
Operating profit/(loss)	(6,515,620)	(3,003,839)	(4,985,999)
Finance income	9,204		39
Finance costs	(13,761)	(21,631)
Income tax expense
Profit/(loss) for the year	(6,520,177)	(3,025,470)	(4,985,960)
Assets
Segment assets	25,159,280	3,354,435	5,324,489
Total assets	25,159,280	3,354,435	5,324,489
Liabilities
Segment liabilities	629,827	426,781	797,155
Total liabilities	$ 629,827	$ 426,781	$ 797,155

Segment Reporting (Details) -_2

Segment Reporting (Details) - Schedule of information on geographical regions - AUD ($)	12 Months Ended
	Jun. 30, 2021		Jun. 30, 2020	Jun. 30, 2019
Segment Reporting (Details) - Schedule of information on geographical regions [Line Items]
Hyperimmune products revenue	$ 145,776	[1]	$ 2,518,566
Revenue from external customers	145,776		2,518,566	$ 2,387,426
Segment revenue				2,387,426
Travelan [Member] | Australia [Member]
Segment Reporting (Details) - Schedule of information on geographical regions [Line Items]
Hyperimmune products revenue	(10,308)	[1]	1,240,393
Revenue from external customers	(10,308)		1,240,393	1,162,628
Segment revenue				1,162,628
Travelan [Member] | United States [Member]
Segment Reporting (Details) - Schedule of information on geographical regions [Line Items]
Hyperimmune products revenue	4,264	[1]	926,325
Revenue from external customers	4,264		926,325	1,016,468
Segment revenue				1,016,468
Travelan [Member] | Other [Member]
Segment Reporting (Details) - Schedule of information on geographical regions [Line Items]
Hyperimmune products revenue	101,639	[1]	301,915
Revenue from external customers	101,639		301,915	149,283
Segment revenue				149,283
Protectyn [Member] | Australia [Member]
Segment Reporting (Details) - Schedule of information on geographical regions [Line Items]
Hyperimmune products revenue	50,181	[1]	49,933
Revenue from external customers	50,181		49,933	58,683
Segment revenue				58,683
Protectyn [Member] | Other [Member]
Segment Reporting (Details) - Schedule of information on geographical regions [Line Items]
Hyperimmune products revenue		[1]
Revenue from external customers				364
Segment revenue				$ 364
[1]	Returns are provided where outlined in a customer’s agreement.

Segment Reporting (Details) -_3

Segment Reporting (Details) - Schedule of major customers - AUD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Segment Reporting (Details) - Schedule of major customers [Line Items]
Total revenue for major customers	$ 140,022	$ 1,898,982	$ 2,015,851
Customer A [Member]
Segment Reporting (Details) - Schedule of major customers [Line Items]
Total revenue for major customers	41,040
Customer B [Member]
Segment Reporting (Details) - Schedule of major customers [Line Items]
Total revenue for major customers	27,563
Customer C [Member]
Segment Reporting (Details) - Schedule of major customers [Line Items]
Total revenue for major customers	25,319
Customer D [Member]
Segment Reporting (Details) - Schedule of major customers [Line Items]
Total revenue for major customers	23,214	462,490	611,920
Customer E [Member]
Segment Reporting (Details) - Schedule of major customers [Line Items]
Total revenue for major customers	22,886
Customer F [Member]
Segment Reporting (Details) - Schedule of major customers [Line Items]
Total revenue for major customers		442,916	228,661
Customer G [Member]
Segment Reporting (Details) - Schedule of major customers [Line Items]
Total revenue for major customers		438,065	659,637
Customer H [Member]
Segment Reporting (Details) - Schedule of major customers [Line Items]
Total revenue for major customers		327,559	266,111
Customer I [Member]
Segment Reporting (Details) - Schedule of major customers [Line Items]
Total revenue for major customers		$ 227,952	$ 249,522

Cash Flow Information (Details)

Cash Flow Information (Details) - Schedule of reconciliation of cash flow from operations with loss after income tax - AUD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Schedule of reconciliation of cash flow from operations with loss after income tax [Abstract]
Net Loss for the Year	$ (8,384,465)	$ (2,927,206)	$ (4,656,421)
Adjustments for
Depreciation expense	43,662	44,056	5,287
Distribution costs		70,000	70,000
Expected credit losses	(30,055)	(3,991)	34,046
Finance costs	13,761	21,631
Finance income	(9,204)		(39)
Leave provision expense	53,610	19,717	4,580
Share-based payments (income)/expenses	2,116,013	(533,912)	1,343,500
Unrealized net foreign currency gains	592,243	(18,883)	(62,015)
Change in operating assets and liabilities:
Add decrease in trade and other receivables	23,037	641,236	680,337
Add (increase) / decrease in inventories	960,920	(113,635)	263,365
Add (increase) / decrease in other operating assets	(45,065)	16,096	92,510
Add (decrease) / increase in trade and other payables	586,796	(362,437)	426,271
Total	$ (4,078,747)	$ (3,147,328)	$ (1,798,579)

Share-based Payments (Details)

Share-based Payments (Details) - USD ($)	1 Months Ended	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2021	Jun. 30, 2020
Disclosure of share-based payment arrangements [text block] [Abstract]
Option granted, description		Options granted to a former managing director on 11 February 2019 and valued at $975,000 in the 30 June 2019 financials were subject to shareholder approval. In line with IFRS 2, these were re-measured at grant date 6 November 2019 after being approved by shareholders with a value of $368,000, being a revaluation of $607,000 in the 30 June 2020 financials.
Revaluation financials amount	$ 607,000	$ 607,000
Shares issued to directors for the director fees		$ 145,913	$ 73,088

Share-based Payments (Details)

Share-based Payments (Details) - Schedule of movement in number of stock options outstanding and weighted average exercise price - $ / shares	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Schedule of movement in number of stock options outstanding and weighted average exercise price [Abstract]
Average exercise price per share option, As at 1 July	$ 0.4	$ 0.46	$ 0.45
Number of options, As at 1 July	42,807,118	79,463,744	72,569,180
Average exercise price per share option, Granted during the year	$ 0.28	$ 0.18	$ 0.47
Number of options, Granted during the year	11,560,000	542,600	9,100,000
Average exercise price per share option, Exercised during the year	$ 0.23	$ 0.18
Number of options, Exercised during the year	(4,057,640)	(424,840)
Average exercise price per share option, Forfeited/lapsed during the year	$ 0.5	$ 0.52	$ 0.53
Number of options,Forfeited/lapsed during the year	(5,000,000)	(36,774,386)	(2,205,436)
Average exercise price per share option, As at 30 June	$ 0.31	$ 0.4	$ 0.46
Number of options, As at 30 June	45,309,478	42,807,118	79,463,744
Average exercise price per share option, Vested and exercisable at 30 June	$ 0.31	$ 0.4	$ 0.46
Number of options,Vested and exercisable at 30 June	45,309,478	42,807,118	79,463,744

Share-based Payments (Details_2

Share-based Payments (Details) - Schedule of granted valuation of options - $ / shares	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]
Share options	45,309,478	42,807,118
Share options price per share (in Dollars per share)	$ 1.58	$ 2.28
2012-06-29 [Member]
Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]
Expiry date	Nov. 30, 2021
Exercise price	1.944
Share options	14,493	14,493
2012-06-29 [Member]
Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]
Expiry date	Jan. 17, 2022
Exercise price	1.876
Share options	29,668	29,668
2017-06-13 (warrants) [Member]
Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]
Expiry date	Jun. 13, 2022
Exercise price	USD 0.25
Share options	24,493,200	27,541,200
2018-03-15 [Member]
Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]
Expiry date	Mar. 15, 2023
Exercise price	0.468
Share options	7,897,647	7,897,647
2017-06-09 (warrants) [Member]
Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]
Expiry date	Jun. 8, 2022
Exercise price	USD 0.3125
Share options	198,240	198,240
2018-03-15 [Member]
Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]
Expiry date	Mar. 15, 2023
Exercise price	0.585
Share options	526,510	526,510
2019-05-23 (warrants) [Member]
Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]
Expiry date	May 23, 2024
Exercise price	USD 0.125
Share options	173,600	181,600
2019-07-16 (warrants) [Member]
Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]
Expiry date	Jul. 16, 2024
Exercise price	USD 0.125
Share options	116,120	117,760
2018-07-13 [Member]
Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]
Expiry date	Jul. 1, 2021
Exercise price	0.500
Share options	1,200,000	1,300,000
2019-11-06 [Member]
Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]
Expiry date	Feb. 10, 2024
Exercise price	0.500
Share options		5,000,000
2020-10-29 [Member]
Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]
Expiry date	Apr. 14, 2024
Exercise price	0.12
Share options	8,100,000
2020-07-24 (warrants) [Member]
Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]
Expiry date	Jul. 21, 2025
Exercise price	USD 0.5859
Share options	2,560,000

Share-based Payments (Details_3

Share-based Payments (Details) - Schedule of granted valuation of options - $ / shares	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]
No. of options	11,560,000	5,000,000	8,300,000
Exercise Price One [Member]
Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]
Grant date	Jul. 24, 2020	Nov. 6, 2019	Jul. 13, 2018
Expiry date	Jul. 21, 2025	Feb. 10, 2024	Jul. 1, 2021
Exercise price	$ 0.83	$ 0.5	$ 0.5
No. of options	2,560,000	5,000,000	1,300,000
Share price at grant date	$ 0.5	$ 0.15	$ 0.32
Expected volatility	127.93%	98.00%	92.00%
Dividend yield	0.00%	0.00%	0.00%
Risk- free interest rate	0.43%	0.88%	2.09%
Fair value at grant date per option	$ 0.4035	$ 0.0736	$ 0.157
Exercise Price Two [Member]
Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]
Grant date	Oct. 29, 2020		Nov. 26, 2018
Expiry date	Apr. 14, 2024		Jun. 30, 2020
Exercise price	$ 0.12		$ 0.5
No. of options	9,000,000		2,000,000
Share price at grant date	$ 0.25		$ 0.34
Expected volatility	142.70%		92.00%
Dividend yield	0.00%		0.00%
Risk- free interest rate	0.13%		2.02%
Fair value at grant date per option	$ 0.2189		$ 0.0822
Exercise Price Three [Member]
Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]
Grant date			Feb. 11, 2019
Expiry date			Feb. 11, 2024
Exercise price			$ 0.5
No. of options			5,000,000
Share price at grant date			$ 0.29
Expected volatility			100.00%
Dividend yield			0.00%
Risk- free interest rate			1.69%
Fair value at grant date per option			$ 0.195

Share-based Payments (Details_4

Share-based Payments (Details) - Schedule of total expenses arising from share-based payment transactions - AUD ($)		12 Months Ended
		Jun. 30, 2021	Jun. 30, 2020	[1]	Jun. 30, 2019
Schedule of total expenses arising from share-based payment transactions [Abstract]
Options issued under ESOP		$ 1,970,100	$ (607,000)		$ 1,343,500
Share-based payments to directors2	[2]	145,913	73,088
Total		$ 2,116,013	$ (533,912)		$ 1,343,500
[1]	Options granted to a former managing director on 11 February 2019 and valued at $975,000 in the 30 June 2019 financials were subject to shareholder approval. In line with IFRS 2, these were re-measured at grant date 6 November 2019 after being approved by shareholders with a value of $368,000, being a revaluation of $607,000 in the 30 June 2020 financials.
[2]	Due to the ongoing crisis of COVID-19, the groups directors decided to forgo cash payments of their director fees and instead receive shares of that value. As at 30 June 2021, shares have been issued to directors for the director fees of $145,913 incurred during the financial year ended 30 June 2021 and $73,088 incurred during the financial year ended 30 June 2020, given the shareholders' approval at the AGM held on 29 October 2020.

Related Party Transactions (Det

Related Party Transactions (Details)	Jul. 01, 2020USD ($)	Jan. 31, 2017AUD ($)	Jan. 31, 2016AUD ($)	Jun. 30, 2021AUD ($)$ / shares	Jun. 30, 2020AUD ($)shares	Jun. 30, 2019AUD ($)shares
Wattle Laboratories Pty Ltd [Member]
Related Party Transactions (Details) [Line Items]
Rental expense				$ 40,607	$ 41,369	$ 53,958
Lease renewed				Jan. 1, 2019
Wattle Laboratories Pty Ltd [Member] | Short-term Funding Agreements [Member]
Related Party Transactions (Details) [Line Items]
Rental expense		$ 39,525	$ 38,940
Grandlodge Capital Pty Ltd [Member]
Related Party Transactions (Details) [Line Items]
Warehousing, distribution and invoicing services	$ 70,000			$ 70,000
Share issued price per share (in Dollars per share) | $ / shares				$ 0.16
Warehousing distribution and services fees					$ 100,978	$ 93,678
Ordinary shares issued (in Shares) | shares					437,500	437,500

Related Party Transactions (D_2

Related Party Transactions (Details) - Schedule of information about other related party transactions - AUD ($)		12 Months Ended
		Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Related Party Transactions (Details) - Schedule of information about other related party transactions [Line Items]
Purchases of various goods and services from entities controlled by key management personnel	[1]	$ 110,607	$ 142,347	$ 147,636
Other transactions with key management personnel		110,607	142,347	147,636
Rental of an office suite from Wattle Laboratories Pty Ltd [Member]
Related Party Transactions (Details) - Schedule of information about other related party transactions [Line Items]
Other transactions with key management personnel		40,607	41,369	53,958
Services rendered by Grandlodge Capital Pty Ltd [Member]
Related Party Transactions (Details) - Schedule of information about other related party transactions [Line Items]
Other transactions with key management personnel		$ 70,000	$ 100,978	$ 93,678
[1]	Purchases from entities controlled by key management personnel

Related Party Transactions (D_3

Related Party Transactions (Details) - Schedule of outstanding balances transactions between related parties - AUD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Current payables (purchases of goods and services)
Entities controlled by key management personnel	$ 70,000

Financial Risk Management Obj_3

Financial Risk Management Objectives and Policies (Details)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure of financial risk management [text block] [Abstract]
Percentage of USD/AUD exchange rate	4.90%	3.30%

Financial Risk Management Obj_4

Financial Risk Management Objectives and Policies (Details) - Schedule of foreign currency risk	Jun. 30, 2021USD ($)	Jun. 30, 2021CAD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2020CAD ($)	Jun. 30, 2020ILS (₪)
United States [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of foreign currency risk [Line Items]
Cash and cash equivalents	$ 2,742,688		$ 2,954,589
Trade receivables	23,801		45,591
Trade payables	18,556		29,946
Total exposure	$ 2,785,045		$ 3,030,126
CAD [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of foreign currency risk [Line Items]
Cash and cash equivalents		$ 108,688		$ 107,605
Trade receivables
Trade payables		43,466		1,923
Total exposure		$ 152,154		$ 109,528
ILS [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of foreign currency risk [Line Items]
Trade receivables | ₪
Trade payables | ₪					41,771
Total exposure | ₪					₪ 41,771

Financial Risk Management Obj_5

Financial Risk Management Objectives and Policies (Details) - Schedule of exchange rates - AUD ($)	Jun. 30, 2021	Jun. 30, 2020
Schedule of exchange rates [Abstract]
Impact on loss for the period	$ 136,467	$ 99,994
Impact on other components of equity	$ 5,219	$ 4,035

Financial Risk Management Obj_6

Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables - Trade Receivables [Member] - AUD ($)	Jun. 30, 2021	Jun. 30, 2020
Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables [Line Items]
Expected credit loss rate
Gross carrying amount	$ 28,553	$ 49,519
Loss allowance		$ 30,055
Current [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables [Line Items]
Expected credit loss rate	0.00%	0.60%
Gross carrying amount	$ 23,801	$ 2,820
Loss allowance		$ 17
1-30 [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables [Line Items]
Expected credit loss rate	0.00%	8.06%
Gross carrying amount	$ 4,752	$ 1,055
Loss allowance		$ 85
31-60 [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables [Line Items]
Expected credit loss rate	13.07%	0.00%
Gross carrying amount
Loss allowance
61-90 [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables [Line Items]
Expected credit loss rate	21.88%	23.35%
Gross carrying amount		$ 14,476
Loss allowance		$ 3,380
91-120 [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables [Line Items]
Expected credit loss rate	34.09%	38.30%
Gross carrying amount		$ 7,447
Loss allowance		$ 2,852
121+ [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables [Line Items]
Expected credit loss rate	53.58%	100.00%
Gross carrying amount		$ 23,721
Loss allowance		$ 23,721

Financial Risk Management Obj_7

Financial Risk Management Objectives and Policies (Details) - Schedule of contractual undiscounted cash flows - AUD ($)	Jun. 30, 2021	Jun. 30, 2020
Less than 6 months [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of contractual undiscounted cash flows [Line Items]
Trade and other payables	$ 132,514	$ 173,663
Lease liabilities	20,498	20,890
Total	153,012	194,553
Total contractual cash flows [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of contractual undiscounted cash flows [Line Items]
Trade and other payables	132,514	173,663
Lease liabilities	20,498	63,462
Total	153,012	237,125
Carrying amount (assets)/ liabilities [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of contractual undiscounted cash flows [Line Items]
Trade and other payables	132,514	173,663
Lease liabilities	20,498	63,462
Total	153,012	237,125
6 - 12 months [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of contractual undiscounted cash flows [Line Items]
Trade and other payables
Lease liabilities		21,286
Total		21,286
Between 1 and 2 years [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of contractual undiscounted cash flows [Line Items]
Trade and other payables
Lease liabilities		21,286
Total		21,286
Between 2 and 5 Years [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of contractual undiscounted cash flows [Line Items]
Trade and other payables
Lease liabilities
Total
Over 5 years [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of contractual undiscounted cash flows [Line Items]
Trade and other payables
Lease liabilities
Total